,ID,Event Name,Publication Status 4,Fourth DOI #,Publication Status 5,Fifth DOI #,Publication Status 6,Sixth DOI #,Publication Status 7,Seventh DOI #,Publication Status 8,Eighth DOI #,Publication Status 9,Ninth DOI #,Publication Status 10,Tenth DOI #,Pedal Non-Peer Pubs,Other Accomplishments,Health Benefits,International,National,Local,General Public,Healthcare Professionals,Patients,Patient Families,Health Benefits Description,Policy Influence,International (pol),National (pol),Local (pol),General Public (pol),Healthcare Professionals (pol),Patients (pol),Patient Families (pol),Policy Benefits Description,Economic Benefits,International (econ),National (econ),Local (econ),General Public (econ),Healthcare Professionals (econ),Patients (econ),Patient Families (econ),Economic Benefits Description,Equity Benefits,International (equity),National (equity),Local (equity),General Public (equity),Healthcare Professionals (equity),Patients (equity),Patient Families (equity),Equity Benefits Description,Additional Funding Achieved,First AFS Status,First AFS Name and Project Title,First AFS Amount,Second AFS Status,Second AFS Name and Project Title,Second AFS Amount,Third AFS Status,Third AFS Name and Project Title,Third AGS Amount,Fourth AFS Status,Fourth AFS Name and Project Title,Fourth AFS Amount,Additional Funding Source #5 Agency/Sponsor Name and Project Title,Fifth AFS Status,Fifth AFS Amount,Additional Pedal Funding Impact,Additional Funding Benefits Description,Additional Pedal Funding Impact (clinical stages),Additional Funding Benefits Description (clinical stages),Participated in Pedal,Further Research Contributions,Success Stories,Major Scientific Breakthroughs,Additional Comments,Complete,Publication Status 1,First DOI #,Publication Status 2,Second DOI #,Publication Status 3,Third DOI #
0,3.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,We have identified some genes that are recurrently dysregulated in neuroblastoma and which have decreased expression in stage 4 disease. These genes are potentially novel tumor suppressors and could help open new therapeutic avenues that eventually benefit patients.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH R35HG011315 Using genomic perturbations to understand trait-associated human genetic variation,1500000.0,,,,,,,,,,,,,Yes,Additional funding would enable the application of the methods we developed to new datasets as well as the analysis of other types of gene dysregulation (such as altered splicing). ,Yes,"In addition, funding could allow us to do more functional testing of the candidate tumor suppressor genes that we identified.","Yes, I have participated as a rider every year since 2016 (virtual rider last year).",No,No,,,True,Accepted,,,,,
1,4.0,Progress Report #1,,,,,,,,,,,,,,,"     Adam K. Fuhs S, Meisenhelder J,  Lesperance J, Aslanian A, Diedrich J, Moresco J,  La Clair J, Zage P, Yates JR III, Hunter T. A Novel  Role for Histidine Kinase Activity in  Neuroblastoma Pathogenesis. Presented at  the 11th International Congress on  NME/NDPK/NM23/AWD gene family; Annecy,  France, October 2019         Adam K, Fuhs S, Meisenhelder J,  Lesperance J, Aslanian A, Diedrich J, Moresco J,  La Clair J, Zage P, Yates JR III, Hunter T. Chasing  the not so Elusive Histidine Phosphorylation  and Their Signaling in Neuroblastoma.  Presented at the 12th Annual World Protein &  Peptide Conference, Beijing, China, June 2019         Adam K, Fuhs S, Meisenhelder J,  Lesperance J, Aslanian A, Diedrich J, Moresco J,  La Clair J, Zage P, Yates JR III, Hunter T. Chasing  the not so Elusive Histidine Phosphorylation  and Their Signaling in Neuroblastoma.  Presented at the Advances in Biomedical  Research III, Split, Croatia, June 2019         Adam K. et al. ""Histidine kinases and the  missing phosphoproteome from prokaryotes  to eukaryotes."" Presented at the American  Society for Biochemistry and Molecular  Biology annual meeting, San Diego, CA, 2018",,Yes,True,False,False,False,False,False,False,"We expect our results will confirm the critical role of NME1 in neuroblastoma tumor development, growth, and spread and will serve to identify candidate therapeutic targets for currently available drugs as well as for the development of novel histidine kinase inhibitors that are likely to be effective against a wide range of pediatric and adult tumors.  These novel therapies and treatment approaches would serve to improve outcomes for children with neuroblastoma and other solid tumors worldwide.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Five,Awarded,the Hartwell Foundation,300000.0,Awarded,Padres Pedal the Cause,100000.0,Submitted,Pediatric Cancer Research Foundation,750000.0,Submitted,NIH R03CA273629-01,150000.0,Tower Cancer Research Foundation,Submitted,500000.0,Yes,"Additional funding support would allow us to pursue studies to further identify and validate NME1-mediated signaling pathways in neuroblastoma preclinical models, to further pursue the functional significance of NME1 and histidine kinase signaling in pediatric tumor development, growth, and spread, and to identify novel candidate targets for therapies directed against targets of NME1 histidine kinase activity",Yes,"Additional funding support would allow us to pursue screening studies at the Sanford  Burnham Prebys Medical Discovery Institute to identify candidate histidine kinase inhibitors that could be evaluated and developed as candidate therapeutic agents, eventually leading to animal studies and early phase clinical trials to evaluate the safety and efficacy of histidine kinase inhibitors in children with cancer.",I have participated as both a virtual participant and as a participant in spin classes at Petco Park,Yes,No,,Funding from Padres Pedal the Cause has been instrumental in building and maintaining my research laboratory and  scienti#c productivity in San Diego and has  been greatly appreciated!,True,Accepted,,Submitted,,,
2,5.0,Progress Report #1,,,,,,,,,,,,,,,None to date,additional funding provided by Padres Pedal the Cause will allow us to open this clinical trial at additional national sites to increase enrollment and ensure timely study completion,Yes,True,False,False,False,False,False,False,We expect our results will support the use of cabozantinib with 13-cis-retinoic acid as a well-tolerated therapeutic option for all patients with relapsed or refractory neuroblastoma worldwide and lead to additional international clinical trials to evaluate the efficacy of this combination as a component of standard neuroblastoma therapy.,No,False,False,False,False,False,False,False,,Yes,False,True,False,False,False,False,False,"The combination of cabozantinib with 13-cis-retinoic acid as a therapeutic option for patients with relapsed or refractory neuroblastoma represents a lower cost, outpatient therapy to reduce the overall cost of treatment",No,False,False,False,False,False,False,False,,One,Awarded,"Exelixis, Inc.",250000.0,,,,,,,,,,,,,Yes,"Additional funding support would allow us to expand the trial to invite and include additional hospitals to open the study and allow us to increase the expected number of enrolled patients to accrue additional information about the safety and efficacy of this combination, as well as obtaining additional samples for the proposed experimental aims and objectives.",Yes,"Additional funding support would allow us to pursue additional clinical trials to evaluate the safety and efficacy of this combination in patients with neuroblastoma as part of standard therapy as well as clinical trials in children with other types of cancer, leading to expanded indications for use of this combination therapy.",I have participated as both a virtual participant and as a participant in spin classes at Petco Park,Yes,Yes,Yes,Funding from Padres Pedal the Cause has been instrumental in building and maintaining my research laboratory and scientific productivity in San Diego and has been greatly appreciated!,True,Published,,,,,
3,6.0,Progress Report #1,,,,,,,,,,,,,,,,See above in the progress report.,Yes,True,True,False,False,False,True,True,oral cancer prevention in at risk individuals,No,False,False,False,False,False,False,False,,Yes,True,True,False,False,False,True,True,"Oral cancer prevention and the consequent reduction in morbidity, mortality, and patient related costs ",Yes,True,True,False,False,False,True,True,At risk oral cancer patients are often part of a  socioeconomically disadvantaged group,One,Submitted,"NIH R01, will likely be funded soon",2500000.0,,,,,,,,,,,,,Yes,For advancing the planned clinical trial and correlative/mechanistic studies ,Yes,Identification of biomarkers predicting clinical response,Yes,No,No,,Many thanks for all your support!!!,True,In progress,,In progress,,,
4,8.0,Progress Report #1,,,,,,,,,,,,,,,"8.Ghali F, Patel D, Jamieson C, Parsons JK, McKay RR. Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer. Poster presentation at the Genitourinary Cancers Symposium, San Francisco, CA; February 2020.","2019-present Member, Wnt Signaling in Prostate Cancer Working GroupProstate Cancer Foundation ",Yes,False,False,False,False,False,True,False,Trial is testing a therapeutic combination for men with prostate cancer. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,False,False,False,False,False,True,False,Trial focused on all demographic of prostate cancer with unique look at Hispanic individuals.,One,Awarded,Oncternal ,377000.0,,,,,,,,,,,,,Yes,This is a grass roots project. It is a single arm study looking to investigate a combination strategy in prostate cancer for patients. Additional funding would help support the correlative studies for the trial.,No,,"Yes, runner. ",Yes,No,,,True,,,,,,
5,9.0,Progress Report #1,,,,,,,,,,,,,,,none,none,Yes,True,True,True,True,False,True,False,novel therapy for cancer,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,True,True,True,True,False,True,False,People from all backgrounds would benefit from this potential therapy.,No additional funding sources,,,,,,,,,,,,,,,,Yes,We could further develop the antibody and optimize it for use in humans.,Yes,Further funding would allow progress towards a clinical trial.,I participated as a rider and a virtual rider in certain years.,No,No,,,True,,,,,,
6,10.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,True,False,False,False,A platform to develop cell-selective targeting peptides as novel strategies for enhanced therapeutic outcomes and to attenuate systemic drug toxicities.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,The Lustgarten Foundation,5000000.0,,,,,,,,,,,,,Yes,Funds would be used for additional in vivo studies including performing a survival study in a PDAC mouse model.,Yes,"Additional funds would support more in vivo studies required advance the concept further to the clinc. These include PK studies, safety, Tox, and proof of principal of the therapeutic advancement over existing free drug version.","yes -  I participate, along with my wife, on the Salk's ride team for Pedal the Cause.  We look forward to the event each year.",No,No,,We are grateful for the support of Padres  Pedal the Cause!,True,In progress,,In progress,,,
7,11.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,True,False,GC treatment,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,True,False,False,False,False,True,True,GC affects certain ethnicities much more than others. Impact of our discoveries are expected to track that. ,One,Awarded,Torey Pines Foundation,1800000.0,,,,,,,,,,,,,Yes,To initiate trials,Yes,Clinical trial initiation at UCSD,donated.,No,No,,,True,In progress,,,,,
8,12.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,True,False,False,False,Awareness of cellular dependencies downstream of oncogenes. This helps in discussions with patients about the pathways important in cancer. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,We are planning an NCI PO1 submission,Yes,More preclinical optimization of lead compound for possible drug testing.,"yes, virtual rider",No,No,,appreciate of the support to create the necessary data for our PO1 project,True,In progress,,,,,
9,13.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,True,False,True,False,"Our project seeks to establish new ways to ascertain if a particular immune checkpoint blockade treatment will be effective in treating certain classes of patients.  If successful, we believe that this study can help tailor therapies to individual patients.  It might also give us insights into the reasons some treatments are effective while others aren't.",Yes,False,False,False,True,False,True,False,Our project could improve guidelines as to how patients are treated with immune checkpoint blockade treatment.,Yes,False,False,False,True,False,True,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,,No,No,,,True,,,,,,
10,14.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,True,False,False,False,True,False,We expect that we will be able to use the organoids to define molecular features of chronic pancreatitis that predict progression to cancer. These can potentially be used for early diagnosis or prevention/treatment.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"We still have a lot of work to do. COVID did slow the rate of tissue acquisition.  Now that we have learned that pancreatic fluid is actually a better source of organoids than tissue, we have started enrolling patients undergoing endoscopic drainage, which will further increase the rate at which we can develop this resource.",Yes,Same as above,"Yes, every year.  This is an awesome event.  This year I plan to run instead of bike.",No,No,,Thanks for your support!,True,,,,,,
11,15.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,These studies will find novel therapies to treat childhood cancer.   ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH,1900000.0,,,,,,,,,,,,,Yes,"The funding from Padres Pedal helped in generating preclinical data on Syk inhibitors with radiation. With additional funding, we will study the efficacy of Syk inhibitors with current frontline therapies and will take these studies into clinical trials for neuroblastoma patients. ",Yes, We will use the additional funding to set up clinical trials of Syk inhibitors with frontline therapies of NB. We already have set up a collaboration with the pharma company that owns FDA approved Syk inhibitor and we can easily translate these studies from bench to bedside.,,No,No,,,True,Published,10.3390/cancers13040817,Published,10.1016/j.pharmthera.2022.108114,In progress,
12,16.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,our molecular analysis will benefit patients with newly diagnosed and refractory medulloblastoma and will serve as a model for other tumor types,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Additional funds could be utilized to enroll more patients,Yes,The funding would allow for more patients to be enrolled.,It was an amazing experience as a virtual rider due to covid.,Yes,Yes,Yes,I have sincerely appreciated the opportunity to work with Padres Pedal the cause over the years. I have taken a major leadership position at childrens hospital orange county and hope to collaborate with the San Diego group and we will be added as a site and will continue to support the effort.,True,In progress,,,,,
13,17.0,Progress Report #1,In progress,Data Collection/Image Analysis: Strain Analysis,,,,,,,,,,,,,,,Yes,False,False,True,False,True,True,False,Improved screening procedures for childhood cancer survivors at risk for heart failure,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"We seek to build upon our results through an analysis of the association of physical activity/exercise with cardiac remodeling and heart function in childhood cancer survivors who received anthracycline therapy. An improved understanding of the role of physical activity will help inform the potential benefit of increased exercise, and a potential exercise intervention. ",Yes,"The goal would be to leverage the additional preliminary data toward understanding the relationship between physical activity/exercise with cardiac remodeling and function, with preliminary results used to gain funding to study an exercise intervention to prevent heart failure n this population.",No but I would like to (please provide me with information),No,No,,I have one grant currently under review (scored in June) and another that will be submitted this summer. Initial submissions were well received but missed paylines. I hope to share positive news with the committee after receiving those results. I also hope to update the committee by the summer/fall with news of further publication(s).,True,Accepted,10.1042/CS20200301,Accepted,10.1182/hematology.2021000268,In progress,Analysis Phase: Conventional MRI analysis
14,18.0,Progress Report #1,,,,,,,,,,,,,,,"Adam K. Fuhs S, Meisenhelder J, Lesperance J, Aslanian A, Diedrich J, Moresco J, La Clair J, Zage P, Yates JR III, Hunter T. A Novel Role for Histidine Kinase Activity in Neuroblastoma Pathogenesis. Presented at the 11th International Congress on NME/NDPK/NM23/AWD gene family; Annecy, France, October 2019    Adam K, Fuhs S, Meisenhelder J, Lesperance J, Aslanian A, Diedrich J, Moresco J, La Clair J, Zage P, Yates JR III, Hunter T. Chasing the not so Elusive Histidine Phosphorylation and Their Signaling in Neuroblastoma. Presented at the 12th Annual World Protein & Peptide Conference, Beijing, China, June 2019    Adam K, Fuhs S, Meisenhelder J, Lesperance J, Aslanian A, Diedrich J, Moresco J, La Clair J, Zage P, Yates JR III, Hunter T. Chasing the not so Elusive Histidine Phosphorylation and Their Signaling in Neuroblastoma.  Presented at the Advances in Biomedical Research III, Split, Croatia, June 2019    Adam K. et al. ""Histidine kinases and the missing phosphoproteome from prokaryotes to eukaryotes."" Presented at the American Society for Biochemistry and Molecular Biology annual meeting, San Diego, CA, 2018",,Yes,True,False,False,False,False,False,False,"We expect our results will confirm the critical role of NME1 in neuroblastoma tumor development, growth, and spread and will serve to identify candidate therapeutic targets for currently available drugs as well as for the development of novel histidine kinase inhibitors that are likely to be effective against a wide range of pediatric and adult tumors.  These novel therapies and treatment approaches would serve to improve outcomes for children with neuroblastoma and other solid tumors worldwide.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Four,Awarded,Hartwell Foundation,300000.0,Submitted,Pediatric Cancer Research Foundation,750000.0,Submitted,NIH R03CA273629-01,150000.0,Planned,NIH R01,2000000.0,none,Submitted,,Yes,"Additional funding support would allow us to pursue studies to further identify and validate NME1-mediated signaling pathways in neuroblastoma preclinical models, to further pursue the functional significance of NME1 and histidine kinase signaling in pediatric tumor development, growth, and spread, and to identify novel candidate targets for therapies directed against targets of NME1 histidine kinase activity",Yes,"Additional funding support would allow us to pursue screening studies at the Sanford Burnham Prebys Medical Discovery Institute to identify candidate histidine kinase inhibitors that could be evaluated and developed as candidate therapeutic agents, eventually leading to animal studies and early phase clinical trials to evaluate the safety and efficacy of histidine kinase inhibitors in children with cancer.",I have participated as both a virtual participant and as a participant in spin classes at Petco Park,Yes,No,,Funding from Padres Pedal the Cause has  been instrumental in building and  maintaining my research laboratory and  scienti#c productivity in San Diego and has  been greatly appreciated!,True,Published,,Submitted,"Zage et al, submitted to EBioMedicine",,
15,20.0,Progress Report #1,,,,,,,,,,,,,,,,"Dr. Field was recruited as an Investigator in the Harrington Discovery Institute, and Director of the Physician-Scientist Scholar-Innovator Award Program of the Harrington Discovery Institute at University Hospitals and Case Western Reserve University.",Yes,True,False,False,False,False,False,False,"It is our goal to develop novel therapeutics, but currently this remains work in progress.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Three,Awarded,NIH/NCI R01CA254397 Mechanism Of Action Of A Novel Golgi-Targeted Anti-Cancer Agent,3310103.0,Awarded,Harrington Discovery Institute Golgi GOLPH3 Pathway Inhibitors as Novel Cancer Therapeutics,3500000.0,Awarded,"V Foundation for Cancer Research, Function of Novel Targets of Phosphoinositides in Oncogenic Transformation",80689.0,,,,,,,Yes,"Development of new direct binding assays, and synthesis of new molecules to further explore SAR to produce more potent compounds with better ADME/PK properties.",Yes,"The goal is to develop compounds that are attractive for commercialization, to enable movement toward clinical use.","Yes, participated as a virtual rider and as a volunteer.",Yes,No,,,True,Published,10.1016/j.devcel.2019.05.038,Submitted,,In progress,
16,21.0,Progress Report #1,,,,,,,,,,,,,,,,New preliminary data for extramural funding,Yes,True,False,False,False,False,False,False,The new marker will be useful to predict the risk of colorectal cancer initiation and progression.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Planned,NCI,1500000.0,,,,,,,,,,,,,No,,No,,no,No,No,,,True,Accepted, 10.3390/cells9091980,In progress,,,
17,22.0,Progress Report #1,,,,,,,,,,,,,,,none,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH U01CA260700 INVESTIGATING THE EFFECTS OF STRUCTURAL VARIANTS ON 3D GENOME ORGANIZATION AND GENE,67000.0,,,,,,,,,,,,,Yes,"We had a disruption in obtaining gliobastoma samples once Dr. Rich moved from UCSD. We have now established a collaboration with Thomas L. Beaumont, MD, PhD  Assistant Professor of Neurological Surgery  Deputy Director, Moores Cancer Center Biorepository to obtain more tumor samples.",Yes,Additional funds for epigenomics profiling would give us sufficient power to detect recurrent epigenomic features of Gbm.,,,,,,True,,,,,,
18,23.0,Progress Report #1,,,,,,,,,,,,,,,"1. Harismendy O, Howell S: Ad-Seq, a genome-wide DNA-adduct profiling assay. bioRxiv 2018.",,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,yes. several times,Yes,No,,Thanks for the great support. It was however not quite sufficient given all the other constraints of my research and position. ,True,,,,,,
19,24.0,Progress Report #1,,,,,,,,,,,,,,,AACR Poster presentation April 2022,,Yes,True,False,False,False,False,False,False,"WIll better delineate the burden of clonal hematopoiesis in breast cancer patients, informing the risk of developing secondary malignancies and perhaps, risk of breast cancer recurrence associated with this novel biomarker. ",Yes,True,False,False,False,False,False,False,"WIll better delineate the burden of clonal hematopoiesis in breast cancer patients, informing the risk of developing secondary malignancies and perhaps, risk of breast cancer recurrence associated with this novel biomarker. ",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Additional funding would be used to support a research assistant to help collect follow up information on the study participants. ,No,,"I have participated in every Pedal the Cause ride since its inception. I have led teams from the MCC and led training rides for participants. I have been a ""Gold Jersey"" fundraiser for the ride in the past. ",No,No,,,True,In progress,,,,,
20,25.0,Progress Report #1,,,,,,,,,,,,,,,Presentation at the MCC CT2 lecture series in December of 2021. ,Securing NCI funding for the research project supported by the Pedal for Cause pilot project funding program. ,Yes,True,False,False,False,False,False,False,The project will deliver a rationally designed therapy for Ewing sarcoma Family of Tumors. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH R01CA251414,2047950.0,,,,,,,,,,,,,Yes,Collect patient tumor samples to develop PDX models for drug testing,Yes,Collect patient tumor samples to develop PDX models for drug testing,I have supported a team of riders twice since 2019.,Yes,No,,Thank you for the support.,True,,,,,,
21,26.0,Progress Report #1,,,,,,,,,,,,,,,"Society for Interventional Oncology. Original Research Oral Presentation: Effects of Cryoablation on Hepatocellular Carcinoma Cancer Stem Cells and the Immune Response. (February 2, 2020) New Orleans, LA.  Best Basic Science Poster. ""Percutaneous Cryoablation and Combination Immunoadjuvant Therapy in a Mouse Model of Hepatocellular Carcinoma"" First author: Tyler Mandt. Society for Interventional Oncology Annual Meeting.","Editor's Award for Outstanding Laboratory Investigation. Stress Conditions Induced by Locoregional Therapies Stimulate Enrichment and Proliferations of Liver Cancer Stem Cells. Journal of Vascular Interventional Radiology (JVIR). 2020  Selected to participate in RSNA's 2020 Clinical Trials Methodology Workshop. January 11-17, 2020. Coronado, CA.",Yes,True,True,False,True,False,True,False,It will help to improve locoregional therapies for liver cancer by helping to understand the mechanisms of recurrence and how to reduce it.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,Department of Defense,250000.0,Submitted,NCI,200000.0,,,,,,,,,,Yes,Additional funding would allow us to expand our animal experiements further in order to identify whether combining cancer stem cell inhibitors with immunomodulatory agents would further reduce recurrence,Yes,We have a clinical trial grant that we would like to find funding for that looks at reducing recurrence of liver cancer with cryoablation and immunoadjuvants.  We have another one that uses prolonged nightly fasting to reduce recurrence.,yes - virtual rider and supporter,Yes,No,,,True,In progress,,In progress,,,
22,27.0,Progress Report #1,Published,10.1016/j.brachy.2021.07.001,,,,,,,,,,,,,"Oral presentations:  1.Kallis, K., Jyoti Mayadev, J., Kisling, K., Ray, X., Scanderbeg, D., Brown, D., Moore, K.L., Meyers, S.M. Knowledge-Based Models to Predict Needle Necessity in Cervical Brachytherapy: A Novel Tool to Assist Physician Decision-Making. 66th Annual Meeting of the Canadian Organization of Medical Physicists, Kelowna, Canada, 22-25 June 2021.  2.Cortes, K., Simon, A., Kallis, K., Mayadev, J., Meyers, S., Moore, K., Knowledge-Based Three-Dimensional Dose Prediction for Tandem-And-Ovoid Brachytherapy. Joint AAPM COMP Virtual Meeting, 12-16 July 2020, p. 53116.  3.Meyers, S.M., Yusufaly, T., Simon, A., Covele, B., Brown, D., Scanderbeg, D., Mayadev, J., Moore, K. Brachytherapy for Locally Advanced Cervical Cancer: Using Knowledge-based Models to Predict Dose to Critical Structures. 65th Annual Meeting of the Canadian Organization of Medical Physicists, Kelowna, Canada, 24-27 September 2019.    Poster presentations:  1.Kallis, K., Mayadev, J., Kisling, K., Ray, X., Scanderbeg, D., Brown, D., Yashar, C., Einck, J., Mell, L., Simon, A., Moore, K., Meyers, S. Feasibility of Knowledge-Based Dose Predictions to Inform Needle Supplementation in Cervical Brachytherapy. International Journal of Radiation Oncology Biology Physics 2021;111(3, Supplement):e136.  2.Kallis, K., Brown, D., Scanderbeg, D., Kisling, K., Covele, B., Simon, A., Yashar, C., Einck, J., Mell, L., Mayadev, J., Moore, K., Meyers, S. Can Knowledge-Based Dose Prediction Models Inform Brachytherapy Needle Decision-Making for Cervical Cancer? Joint AAPM COMP Virtual Meeting, 12-16 July 2020, p. 53379.   3.Kallis, K., Covele, B., Simon, A., Brown, D., Scanderbeg, D., Kisling, K., Yashar, C., Einck, J., Mell, L., Mayadev, J., Moore, K., Meyers, S. What Knowledge-Based Dose Prediction Models Tell Us About Ovoid Vs. Ring Based Brachytherapy Applicators. Joint AAPM COMP Virtual Meeting, 12-16 July 2020, p. 53457. (Blue Ribbon Poster)  4.Yusufaly, T., Simon, A., Hild, S., Brown, D., Scanderbeg, D., Mayadev, J., Moore, K., Meyers, S.M. A Knowledge-Based Organ Dose Prediction Tool for Brachytherapy Treatment of Cervical Cancer Patients. 61st Annual Meeting of the American Association of Physicists in Medicine, San Antonio, Texas, 14-18 July 2019.    ","Using the preliminary data collected with the help of this grant, I was able to apply for an NIH K award and received a very high score. I am still awaiting confirmation on whether my application was funded, which I should know by March 2022",Yes,True,True,True,False,True,True,False,"The tools developed from this work could result in patient receiving higher quality treatments with reduced toxicity, and reduce the time patients spend under anesthesia (and therefore reduce the chance of complication)",Yes,True,True,True,False,True,True,False,"These tools can help healthcare professionals with decision-making that impacts the quality and length of patient treatments, by helping them select appropriate brachytherapy devices to implant",Yes,True,True,True,False,True,True,False,"Automated planning could reduce the time patients spend under anesthesia, which reduces hospital resource usage and could reduce costs of brachytherapy procedures",Yes,True,True,True,False,False,False,False,"Currently, under-resourced centers (particularly in third world countries) are not offering brachytherapy, which is partly due to the hospital resources and clinician expertise required for these procedures. The tools developed in this work will improve the ease of this procedure through automation and decision-making guidance, which could allow more centers that lack expertise to offer this very necessary treatment for cervical cancer. ",No additional funding sources,,,,,,,,,,,,,,,,Yes,I would use the funding to hire personnel to develop and test the automated treatment planning. ,Yes,"Once automated treatment planning has been validated on retrospective data, we will need to perform a pilot study to test its efficacy in the clinic real-time, compared to current manual procedures. This will also allow us to determine whether the automation significantly reduces procedure time. Funding would allow us to hire personnel to carry out this pilot study. ","I participated in 2018 as a walker, 2019-20 as a rider and 2021 as a virtual rider. I will also ride in 2022. I have always enjoyed the event. It is well organized and promotes a very positive spirit towards fundraising for such an important cause. ",No,No,,The seed funding received from Padres Pedal the Cause was instrumental to me developing the preliminary data I needed to launch my career as an independent principal investigator and apply for NIH-level grants. I really appreciate Padres Pedal the Cause for supporting important research conducted at our institution! ,True,Published,10.1016/j.brachy.2020.04.008,Published,10.1016/j.semradonc.2020.05.009,Published,10.1016/j.brachy.2021.08.010
23,28.0,Progress Report #1,,,,,,,,,,,,,,,"Petit C, Pathak KV, Leskoske KL, Plaisier S, Torres A, Huo Y, Zage PE, Pirrotte P. Altered Metabolism of Chemoresistant CD114+ Medulloblastoma Stem Cells.  Presented at Helios Scholars at TGen Research Symposium, Phoenix, AZ; August 2021.    Paul MR, Huo Y, Liu A, Lesperance J, Garancher A, Wechsler-Reya R, Zage PE.  Characterization of G-CSF receptor expression in medulloblastoma  Accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, April 2020     Paul M, Lesperance J, Zage PE.  Targeting Granulocyte Colony Stimulation Factor Receptor-Expressing Medulloblastoma Cells.  Presented at the Society for NeuroOncology Pediatric Neuro-oncology Basic and Translational Research Conference, San Francisco, CA, May 2019.  Neuro-Oncology. 21: ii112.    Paul M, Lesperance J, Zage PE.  The Role of G-CSF Receptor Surface Expression in Medulloblastoma Pathogenesis.  Presented at the International Society for Pediatric Neuro-Oncology Annual Meeting, Denver, CO, June 2018.  Neuro-Oncology.  20: 129.    Paul M, Lesperance J, Zage PE.  The Role of G-CSF Receptor Surface Expression in Medulloblastoma Pathogenesis.  Presented at the American Society of Pediatric Hematology/Oncology Annual Meeting, Pittsburgh, PA, May 2018.  Pediatric Blood & Cancer.  65.",,Yes,True,False,False,False,False,False,False,"We expect our results will confirm the critical role of CD114 in medulloblastoma tumor development, growth, and spread and will serve to identify candidate therapeutic targets. Novel therapies directed against CD114-mediated signaling and reduced use of GCSF in children with medulloblastoma would serve to improve outcomes for children with medulloblastoma worldwide.",No,False,False,False,False,False,False,False,,Yes,False,True,False,False,False,False,False,Reduced use of GCSF for supportive care for children with medulloblastoma would serve to both reduce costs of care and improve outcomes for children with medulloblastoma worldwide.,No,False,False,False,False,False,False,False,,Five,Submitted,NIH R03CA277220,150000.0,Submitted,NIH R03CA262934,160000.0,Submitted,NIH R01CA259462,2000000.0,Submitted,NIH R21CA238141,350000.0,NIH R01,Planned,2500000.0,Yes,"Additional funding support would allow us to pursue studies to further identify and validate CD114-mediated signaling and metabolic pathways in medulloblastoma preclinical models, to further pursue the functional significance of CD114 and CD114-mediated signaling in pediatric tumor development, growth, and spread, and to identify novel candidate targets for therapies directed against CD114-mediated signaling.",Yes,"Additional funding support would allow us to identify candidate therapeutic targets that could be evaluated in preclinical models, and agents directed against these targets could be developed as candidate therapies, eventually leading to animal studies and early phase clinical trials to evaluate the safety and efficacy of these agents in children with cancer.",I have participated as both a virtual participant and as a participant in spin classes at Petco Park,Yes,No,,Funding from Padres Pedal the Cause has  been instrumental in building and  maintaining my research laboratory and  scientific productivity in San Diego and has  been greatly appreciated!,True,Accepted,,In progress,,,
24,30.0,Progress Report #1,,,,,,,,,,,,,,,Review article:  DOI: 10.1007/164_2021_529  PMID: 34463853,,Yes,True,False,False,False,False,False,False,The initial characterization of the FZD7 antibody catalyzed two novel therapeutic approaches to treat cancer:  1. FZD7-antibody drug conjugate: this requires further preclinical testing before transitioning to clinical development.  2. Bispecific T-cell engager: Pfizer-CTI has licensed our technology and is developing a novel drug to treat solid tumors.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,The Mary Kay Foundation,100000.0,Awarded,Pfizer-CTI,1200000.0,,,,,,,,,,Yes,The ADC approach requires further preclinical studies in an immune-competent mouse model. We have established such a model in the lab and now need to test the effect of the ADC. Additional funding will help these studies be completed since no other funding source is currently available.,Yes,The aforementioned preclinical studies are a prerequisite to advance toward clinical stages.,Due to the pandemic I was not able to participate in an event.,Yes,No,,The support provided by Pedal the Cause allowed me to develop a viable cancer research program in my lab.,True,Published,10.7554/eLife.63060,Published,10.1158/1535-7163.MCT-21-0548,,
25,31.0,Progress Report #1,,,,,,,,,,,,,,,None,"I used the money to support studies performed by a student in the laboratory, providing valuable experience to this student and helping him with a career in scientific research. He has applied to several top tier PhD programs.",Yes,False,False,False,False,False,True,False,"If cancer with high CCF indeed grow faster, a compound that inhibits CCF could be used to treat patients with cancer.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"Additional funding would be used to determine the mechanism by which tumors with high CCF grow faster. This was an unexpected, opposite result and deserves further study.",Yes,"If we identify the genes induced by CCF in tumors that promote immune infiltration and faster growth, we might identify a pathway that already has approved inhibitors. These approved inhibitors can be tested in pre-clinical studies and clinical trials.",I participated as a runner.,No,No,,"I am incredibly thankful to have received the funding. Although the results completely disproved our original hypothesis, the experiments performed and techniques developed have provided important expertise to our laboratory.",True,,,,,,
26,32.0,Progress Report #1,,,,,,,,,,,,,,,"2018PSGL-1 is a Checkpoint Regulator of Effector, Memory and Exhausted T Cells, Erasmus University, Rotterdam, The Netherlands    2019 Checkpoint Inhibition of T Cells: Insights from Regulation by PSGL-1, Immuno-Oncology Summit, SDCPI, La Jolla, CA    2019A New Perspective on Immune Checkpoint Inhibition; Mechanisms and Models of Cancer, Salk Institute, La Jolla, CA    2021PSGL-1 Limits TCR Signaling, and Glycolytic Metabolism to Constrain T Cell Responses and Promote Terminal Exhaustion, University of Colorado, Denver, CO  ",This grant led to grants funded by the Department of Defense and the Melanoma Research Alliance to continue the work initiated under the Pedal the Cause to translate our findings that PSGL-1 is a very early inhibitor of T cell signaling that drives T cell exhaustion with chronic antigen stimulation. ,Yes,True,False,False,False,False,False,False,This project has led a funded effort to develop monoclonal antibodies to block PSGL-1 signaling for treatment of a variety of anti-PD-1 resistant cancers. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,Melanoma Research Alliance MRA 696326:Targeting Immune Inhibitory Gene Transcription to Reverse T Cell Exhaustion,100000.0,Awarded,Department of Defense W81XWH-20-1-0324: Multidimensional Reversal of T Cell Exhaustion in Melanoma,584200.0,,,,,,,,,,Yes,Funding is needed to extend our studies to block PSGL-1 as an immunotherapy for melanoma and other solid tumors using humanized mouse models. These studies are needed for clinical translation.,Yes,"The goals are to advance the development of monoclonal anti-PSGL-1 antibodies as an immunotherapy for melanoma and other solid cancers. In new studies of a mouse model of pancreatic cancer that is insensitive to PD-1/PD-1 blockade, we identified that PSGL-1 deficiency enabled significant tumor growth control by preventing the development of T cell exhaustion and supporting the generation/maintenance of a T cell subset that is necessary for responses to immune checkpoint blockade.  We now seek to extend these studies to human patient samples.",I have participated as a virtual rider.,No,No,,This program is has been highly instrumental in launching our efforts to develop a novel immunotherapy for melanoma and other cancers.,True,Submitted,,,,,
27,33.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,True,False,True,False,"Our work investigates the role of common genetic variation in breast cancer risk. Improved projection of cancer risk can inform screening and increase early detection, which ultimately leads to improved outcomes. ",No,False,False,False,False,False,False,False,,Yes,False,False,False,True,False,False,False,"Potentially and in the long term. If our work leads to better risk projection and earlier detection, this can reduce costs associated with managing late stage disease. ",No,False,False,False,False,False,False,False,,One,Awarded,NIH,150000.0,,,,,,,,,,,,,No,,No,,As a Rider twice,No,No,,,True,In progress,,,,,
28,34.0,Progress Report #1,,,,,,,,,,,,,,,,Nothing to add.,Yes,True,False,False,False,False,False,False,Improved treatment of pancreatic cancer.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,We would use the additional funding to validate our results in freshly prepared human PDAC tumor slice cultures,Yes,"Additional funding will enable us to initiate pilot clinical studies using FDA approved drugs such as the antibiotic  tigecycline, which inhibits mitochondrial protein synthesis.",Yes. I participated as a virtual rider.,No,No,,No additional comments.,True,Published,10.1016/j.ccell.2021.02.016,Submitted,,In progress,
29,35.0,Progress Report #1,,,,,,,,,,,,,,,"presentations:    Targeting a therapeutic vulnerability in PTEN-deficient brain tumors. Cancer Therapeutics Training (CT2) Program lecture, La Jolla, CA 2021    Targeting a therapeutic vulnerability in PTEN-deficient brain tumors. SNO annual meeting invited speaker: 2018.  ",The paper (PMID: 33428749) was the subject of an editorial in Neuro-Oncology (PMID: 33864093) and a podcast discussion with the Society for Neuro-Oncology.,Yes,True,True,False,False,False,True,False,"Our finding that PTEN deficient GBM are sensitive to proteasomal inhibitor (PI) compounds should be moved forward with additional pre-clinical studies and eventually a clinical trial with a PI that penetrates the BBB, such as marizomib. ",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"Additional funding would help us refine a transcriptional signature that tracks with proteasomal inhibitor sensitivity.   Such a signature can then be applied to a large bank of GBM and other brain tumors for drug sensitivity validation.  Also, proteasomal inhibition in combination with standard of care therapy would be tried to determine if we achieve further extension in animal survival.  Support for these experiments would be pretext for a clinical trial. ",Yes,"As mentioned above, additional funding would help with: 1) refining a proteasome inhibitor sensitive expression signature; 2) screening a GBM and other brain tumors; 3) testing addition of standard of care therapy. ","Yes, in November 2017 my lab and i participated as riders.  It was an incredible event to see San Diego community come together to support cancer research and treatment.  I would be happy to participate again.",No,No,,,True,Published,10.1093/neuonc/noab001,,,,
30,36.0,Progress Report #1,,,,,,,,,,,,,,,2022 Midwinter Conference of Immunologists,Multiple poster and invited presentations for my graduate student,Yes,True,True,True,False,True,True,False,We describe the mechanistic explanation for ARID1A mutation as a therapeutic biomarker for immunotherapy.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Obtain more human samples with which to translate our findings from mouse,Yes,Establish prospective clinical trials testing efficacy of immunotherapy in ARID1A mutant cancers to identify molecular features of responders versus non-responders,"Yes, rider and virtual rider. My experience has been positive.",No,No,,,True,In progress,,In progress,,,
31,37.0,Progress Report #1,In progress,,Accepted,,Accepted,,Accepted,,Accepted,,Accepted,,Accepted,,"How many additional funding sources did you receive, directly or indirectly, as a result of this Padres Pedal the Cause support? (e.g., grants of any type, awards, philanthropy, etc.)  * must provide value    NCI Mentored Clinical Scientist Research Career Development Award to Promote Faculty Diversity in Biomedical Research (K08CA230306)   (Aristizabal, 9.0 CM)                                                $1,190,451                                            7/1/2018 - 6/30/2023  ""COMPRENDO: Adaptation and Implementation of a Peer-Navigation Intervention to Improve Research Literacy and Diversity in Pediatric Leukemia Clinical Trials"".   The goal of this study is to improve research literacy in parents of children with leukemia, by adapting, implementing and pilot-testing a culturally and linguistically tailored peer-navigation intervention.    NIH/NCI 1R01CA248439-01A1   (Wolfson)              $2,842,545                                      03/24/2021-3/23/2026                                                                                    Predictors of Systemic Exposure to Oral 6MP during Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.   This study investigates adherence to oral therapy and host polymorphisms to understand the causes of disparities in this population.  Role: Site PI, 0.3 CM    Padres Pedal the Cause   (Su, Aristizabal (0.1 C)         $125,000                                     01/01/2022-12/31/2022                                                                                    Evaluation of a Technology Assisted Intervention for Tailoring Oncofertility Care in   Female Cancer Survivors: A Pilot Cluster Randomized Controlled Trial  This study investigates effectiveness and implementation outcomes of an innovative oncofertility intervention.    American Cancer Society  (Kazak)                             $1,638,000                                     01/01/2020- 6/30/2023                                                                ""Implementing Family Psychosocial Risk Screening for Pediatric Health Equity"".   This study investigates the implementation of the psychosocial assessment score in a multicenter study.   Role: Site PI, non-salary    UC San Diego School of Medicine Summer Research Grant (Banerjee)  $5,000          6/01/2021-9/6/2021  ""Food insecurity in children with Sickle Cell Disease or Hemophilia and their families"".   The purpose of this award is to study food insecurity and household material hardship in children with sickle cell anemia and hemophilia and their families.   Role: Mentor to Shreya Banerjee, University of California San Diego medical student, non-salary     UC San Diego Moores Cancer Center Summer Research Grant (Bird)  $5,000          6/01/2021-9/6/2021  ""Health literacy among caregivers of children with cancer and survivors"".   The purpose of this award is to study health literacy in  parents of children with newly diagnosed cancer and childhood cancer survivors.   Role: Mentor to Victoria Bird, University of California San Diego medical student, non-salary     UC San Diego Moores Cancer Center/San Diego State University Partnership U54 Summer Research Grant (Phan)  $5,000          6/01/2021-9/6/2021  ""Barriers and facilitators to informed consent for pediatric cancer clinical trials: Parents' perspectives"".   The purpose of this award is to study barriers and facilitators to adequate informed consent for therapeutic clinical trials in parents of children with newly diagnosed cancer.   Role: Mentor to Nikki Phan, San Diego State University student, non-salary     Rady Children's Hospital Physician Development Fund Award    (Aristizabal)                                                                                            $5,000        10/01/2019-10/31/2022  ""Delivery of informed consent curriculum for pediatric hematology/oncology fellows to enhance communication skills"".   The purpose of this award is to deliver an informed consent curriculum for pediatric hematology/ oncology fellows to enhance communication skills.  Non-salary    Sanofi-Espoir Foundation (Rivera, Aristizabal)          $100,000                                       6/01/2019-12/31/2021  ""PACARSS: Establishment of a Pediatric and Adolescent Cancer Registry-Surveillance System in Mexico"". The purpose of this project is to implement a pediatric cancer surveillance system in Tijuana, Mexico.   Non-salary    UC San Diego Hispanic Center of Excellence Grant (Rocha)  $4,000                            6/01/2019-12/31/2021  ""Food insecurity and household material hardship in families of children with newly-diagnosed cancer"".   The purpose of this award is to study food insecurity and household material hardship in children with newly- diagnosed cancer and their families.   Role: Mentor to Carolyn Rocha, University of California San Diego, non-salary     Sanofi-Espoir Foundation (Ramirez, Aristizabal)                     $320,000                          6/01/2016-12/31/2021  ""Developing and pilot-testing a tool for early detection of cancer in pediatric oncology"".   The purpose of this project is to develop and pilot-test a tool to improve early detection of pediatric cancer cases in Colombia.   Non-salary                Rady Children's Hospital International Outreach Program   (Aristizabal, 1.0 CM)                                                $300,000 /year                                     11/1/2008-Indefenite                                                  ""Establishing a ""Twinning"" program in pediatric oncology in Baja California, Mexico"".   The purpose of this project is to establish and sustain a pediatric oncology program in Tijuana, Mexico using an implementation framework .                                                                                                          UCSD Clinical Translational Research Institute Pilot Grant (Su)  $20,000                 6/01/2020-10/01/2020  ""Developing a multicomponent implementation strategy for fertility care for female adolescent and young adult cancer survivors.""   The purpose of this award is to develop an implementation strategy to improve onco-fertility care.  Role: Co-I, non-salary    National Institutes of Health, Grant TL1TR001443   CTRI UC San Diego Research Summer Grant (Rocha)                $5,000                             6/01/2019-9/01/2019  ""Food insecurity and household material hardship in families of children with newly-diagnosed cancer"".   The purpose of this award is to study food insecurity and household material hardship in children with newly- diagnosed cancer and their families.   Role: Mentor to Carolyn Rocha, University of California San Diego, non-salary      Publications  Direct:   1.Aristizabal P, Winestone LE, Umaretiya P, Bona K. Disparities in Pediatric Oncology: The 21st Century Opportunity to Improve Outcomes in Children and Adolescents with Cancer. Am Soc Clin  Oncol Educ Book. 2021 Jun; 41:e315-e326. doi: 10.1200/EDBK_320499. PMID: 34061564  2.Aristizabal P, Ma AK, Perdomo BP, Thornburg C, Martinez ME, Nodora J. Assessment of Factors associated with Voluntary Parental Decisions about Child Participation in Leukemia Clinical Trials. JAMA Netw Open 2021 May 3; 4(5): e219038. doi: 10.1001/jamanetworkopen.2021.9038. PMID: 33944924  3.Aristizabal P. Diverse populations and enrollment in pediatric cancer clinical trials: Challenges and Opportunities. Pediatr Blood Cancer. 2020; e28296. doi: 10.1002/pbc.28296. PMID: 32343877.    4. Aristizabal P; Nataraj S; Ma A;  Kumar NV; Perdomo BP; Martinez ME; Nodora J;Thornburg CD. Informed Consent Comprehensn Cancer Clinical Trials: Impact of Social Determinants of Health. Pediatrics under review.      Indirect  1.Yang E, Dornisch A, Nerb L, Helsten T, Kaiser BN, Aristizabal P, Armenian S, Torno LL, Baca NM, Genesen MC, Su HI, Romero SAD. A Multi-Component Telehealth Intervention to Improve Oncofertility Care Delivery Among Young Cancer Patients: A Pilot Study. J Adolesc Young Adult Oncol. Under Review  2.Sridhar S, Aristizabal P, Elster J, Crawford J. Single-Agent Bevacizumab in the Treatment of Symptomatic Cervicomedullary Brainstem Low Grade Glioma. J Pediatr Hematol Oncol. Under Review.  3.Rivera-Gomez R, Chang C, Ornelas M, Ramirez M, Tamayo G, Martinez A, Roberts W, Ribeiro RC, Aristizabal P. A World Health Organization Framework Approach to Building Sustainable Leukemia Care in Northwestern Mexico. JCO Oncol Pract. 2021. Under Review.   4.Johnston EE, Martinez I, Davis ES, Caudill C, Richman J, Brackett J, Dickens D, Kahn A, Schwalm C, Sharma A, Patel P on behalf of the POCC Consortium, Bhatia S, Levine J, Wolfson J. SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities [published online ahead of print, 2021 Oct 25].   J Clin Oncol. 2021;JCO2100702. doi:10.1200/JCO.21.00702. (Aristizabal P, Member of POCC Consortium)  7.Shliakhtsitsava K, Stucky-Fisher E, Trovillion EM, Kuo D, Newfield RS, Thornburg CD, Roberts W, Aristizabal P. Improving Vitamin D Screening and Supplementation in Children with Newly-Diagnosed Cancer: A Quality Improvement Initiative at Rady Children's Hospital San Diego. Pediatr Blood Cancer. 2021. 2021 Jul 19:e29217. doi: 10.1002/pbc.29217. PMID: 34286891  8.Gonzalez-Guzman M, Aristizabal P*, Loera A, Torres D, Ornelas M, Nuño L, Aguilera M, Sánchez A, Romano M, Rivera R, Relyea G, Friedrich P, Caniza M. The Golden Hour: Sustainability and Clinical Outcomes of Adequate Time to Antibiotic Administration in Children with Cancer and Febrile Neutropenia in Northwestern Mexico. JCO Global Onc. 2021May; 7:659-670. doi: 10.1200/GO.20.00578. PMID: 33974443.  9.Dornish A, Yang EH, Gruspe J, Roesch ER, Aristizabal P, Aarons GA, Helsten T, Takemoto MB, Romero SAD, Kaiser BN, Su I. Theory-guided Development of Fertility Care Implementation Strategies for Adolescent and Young Adult Cancer Survivors. J Adolesc Young Adult Oncol. 2021 Jan 19. doi: 10.1089/jayao.2020.0156. PMID: 33470879.  10.Aristizabal P, Burns L, Kumar N, Perdomo BP, Rivera R, Ornelas M, Gonda D, Malicki D, Roberts W, Levy ML, Crawford JR. Improving Pediatric Neuro-Oncology Disparities in the US-Mexico Border Region: A Cross-Border Initiative between San Diego, California and Tijuana, Mexico. J Clin Oncol: Global Oncology. 2020 Nov; 6:1791-1802. doi: 10.1200/GO.20.00377. PMID: 33216645.  11.Bhatia S, Hageman L, Chen Y, Wong FL, McQuaid EL, Duncan C, Mascarenhas L, Freyer D, Mba N, Aristizabal P, Walterhouse D, Lew G, Kempert P, Russell TB, McNall-Knapp RY, Jacobs S, Dang H, Raetz E, Relling MV, Landier W. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(8):e2014205. doi:10.1001/jamanetworkopen. 2020.14205. PMID: 32852553.  13.Aristizabal P, Sherer M, Castelao E, Thornburg CT, Proudfoot J, Jacobs ET, Newfield RS, Zage P, Roberts W, Martinez ME. Vitamin D status in newly-diagnosed pediatric cancer patients: Effects of sociodemographic factors, cancer type and supplementation. Pediatr Hematol Oncol. 2020; 10:1-12. doi: 10.1080/08880018.2020.1721629. PMID: 32153233.  14.Ramirez O, Aristizabal P, Zaidi A, Ribeiro RC, Bravo LE. Childhood cancer survival disparities in a universalized healthcare system. J Pediatr Hematol Oncol. 2019; 3(4):78-87. doi.org/ 10.1016/ j.phoj.2019.01.001.  15.Paul MR, Wong V, Aristizabal P, Kuo DJ. Treatment of recurrent refractory pediatric pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance. J Pediatr Hematol Oncol. 2019; 41(8):e546-e549. doi:10.1097/MPH.0000000000001440. PMID: 30807395.  16.Ornelas-Sánchez M, Nuño-Vázquez L, Loera-Reyna A, Torres-Reyes D, Rivera-Gómez R, Sánchez A, Romano M, González M, Caniza MA, Aristizabal P. The ""Golden Hour"": A capacity-building initiative to decrease life-threating complications related to neutropenic fever in patients with hematologic malignancies in low-and middle income countries. Blood Adv. 2018; 2 (Suppl 1):63-66. doi:10.1182/bloodadvances. 2018GS112240. PMID: 30504206 PMCID: PMC6438274.    ","List your presentations, abstracts, book chapters or other publications (non-peer reviewed) associated with Pedal the Cause support   ""Theory-guided Assessment of Barriers and Facilitators to Adequate Informed Consent for Childhood Cancer Clinical Trials: Using the Exploration, Preparation, Implementation, Sustainment (EPIS) Framework"" 2022 American Society of Pediatric Hematology Oncology Annual Meeting.     1.Aristizabal P, Morales J, Rocha C, Nataraj S, Durali N, Kumar N, Ethiraj S, Thornburg C. Trust in Physicians Among Hispanic Caregivers of Children with Newly-Diagnosed Cancer. American Society of Pediatric Hematology/Oncology (ASPHO) Conference; April 20-23, 2021; Portland OR. (Virtual conference due to COVID-19 pandemic).  2.Kumar N, Perdomo B, Nataraj S, Durali N, Morales J, Rocha C, Milburn M, Thornburg C, Aristizabal P. Role of Health Literacy and Socio-demographics on Cancer Knowledge among Parents of Children with Newly-Diagnosed Cancer. American Society of Pediatric Hematology/Oncology (ASPHO) Conference; April 20-23, 2021; Portland, OR. (Virtual conference due to COVID-19 pandemic).  3.Rocha C, Kumar N, Durali N, Aristizabal P. Health Literacy and Household Material Hardship in Families of Children with Newly-Diagnosed Cancer. Health Literacy Annual Research Conference; October 18-20, 2020; College Park, MD. (Virtual Conference due to COVID-19 pandemic).  4.Rocha C, Nataraj S, Kumar N, Perdomo BP, Durali N, Aristizabal P. Socioeconomic and Contextual Factors Associated with Food Insecurity and Household Material Hardship in Families of Children With Newly-Diagnosed Cancer. 52nd Congress of the International Society of Paediatric Oncology (SIOP); October 14-27, 2020; Ottawa, Canada. (Virtual Conference due to COVID-19 pandemic).  5.Aristizabal P, Ma AK, Perdomo BP, Thornburg C. Health Literacy in Parents of Children with Cancer: Comparison of Hispanics and Non-Hispanic-Whites. University of California San Diego Pediatric Research Symposium; May 31, 2020; San Diego, CA.  6.Aristizabal P, Ma AK, Perdomo BP, Thornburg C. Health Literacy in Parents of Children with Cancer: Comparison of Hispanics and Non-Hispanic-Whites. 2nd Annual Inter-professional Innovations Symposium Rady Children's Hospital San Diego; May 29, 2020; San Diego, CA.  7.Rocha C, Nataraj S, Perdomo BP, Durali N, Zhang Y, Thornburg C, Aristizabal P. Food Insecurity and Household Material Hardship in Families of Children With Newly-Diagnosed Cancer. The 2020 American Society of Pediatric Hematology/Oncology (ASPHO) Conference; May 6-9, 2020; Fort Worth, TX. (Conference canceled due to COVID-19 pandemic).  8.Rocha C, Nataraj S, Perdomo BP, Durali N, Zhang Y, Thornburg C, Aristizabal P. Food Insecurity and Household Material Hardship in Families of Children with Newly-Diagnosed Cancer. 2019 UC San Diego Summer Research Training Program Poster Presentation; January 20, 2020; La Jolla, CA.  9.Nataraj S, Perdomo BP, Durali N, Reineke A, Nodora J, Cardenas V, Zhang Y, Thornburg C, Aristizabal P. The Role of Health Literacy on Psychosocial Distress in Caregivers of Children with Newly-Diagnosed Cancer. Health Literacy Research Conference; October 27-30, 2019; San Diego, CA.  10.Aristizabal P, Ma A, Perdomo BP, Martinez ME. Role of Health Literacy on Perception of Voluntariness during Informed Consent for Pediatric Cancer Clinical Trials. 51st Congress of the International Society of Paediatric Oncology (SIOP); October 23-26, 2019; Lyon, France.   11.Aristizabal P, Perdomo BP, Durali N, Nataraj S, Nodora J, Martinez ME. Health Disparities among Hispanic Caregivers of Children with Newly-Diagnosed Cancer. 12th American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 20-23, 2019; San Francisco, CA.  12.Nataraj S, Perdomo BP, Durali N, Reineke A, Zhang Y, Thornburg C, Aristizabal P. Factors Contributing to Psychosocial Distress in Caregivers of Children with Newly-Diagnosed Cancer. American Society of Pediatric Hematology/Oncology Annual Meeting (ASPHO); May, 2019; New Orleans, LA.  13.Durali N, Perdomo BP, Nataraj S, Thornburg C, Aristizabal P. Health Literacy in Parents of Children with Cancer: Comparison of Hispanics and Non-Hispanic-Whites. American Society of Pediatric Hematology/Oncology Annual Meeting (ASPHO); May, 2019; New Orleans, LA.  14.Meyer M, Nguyen J, Perdomo BP, Thornburg CD, Aristizabal P. Role of Health Literacy and Socio-Demographic Factors on Treatment Adherence in Pediatric Patients with Hemophilia and Sickle Cell Anemia. 10th Annual University of California Pediatric Research Symposium; May 29, 2019; San Diego, CA.  15.Zhang Y, Durali N, Perdomo BP, Nataraj S, Thornburg C, Aristizabal P. Association Between Contextual Factors to Health Literacy Level in Caregivers of Newly-Diagnosed Pediatric Cancer Patients. University of California San Diego Public Health Research Day; April, 2019; La Jolla, CA.  16.Meyer M, Nguyen J, Perdomo BP, Aristizabal P. Role of Health Literacy, Mistrust, and Socio-Demographic Factors on Treatment Adherence in Pediatric Patients with Hemophilia and Sickle Cell Anemia. 2019 UC San Diego Annual Summer Research Poster Presentation; January 24, 2019; La Jolla, CA.    ",Yes,False,True,True,True,True,True,True,"Findings could potentially benefit parents' experience, satisfaction, decision-making abilities and comprehension of informed consent in parents of children with cancer participating in therapeutic clinical trials. This intervention will also contribute to reduce disparities in underserved populations.",Yes,False,True,True,True,True,True,True,The navigation intervention could potentially be translated to bedside clinical care and thus be included in training for all providers involved in informed consent processes for therapeutic and non-therapeutic clinical trials. Results can also be translated to adolescents and adults with cancer. ,Yes,False,True,True,True,True,True,True,"The navigation intervention could potentially increase clinical trials accrual and benefit more patients by providing equal access.  By increasing minority participation in clinical trials, we can effectively and equally translate discoveries and treatment benefits. Our results will inform clinical care and the design of a multi-site randomized clinical trial in a larger sample.",Yes,True,True,True,True,True,True,True,"The navigation intervention could potentially increase clinical trials recruitment specifically in populations experiencing disparities. By increasing minority participation in clinical trials, we can effectively and equally translate discoveries and treatment benefits.",Five,Awarded,see below in box,1000000.0,Submitted,below,1000000.0,Awarded,below,125000.0,Awarded,below,125000.0,below,Awarded,1250000.0,Yes,"Absolutely: Future CUREBOUND funding will be critical to expand improvements in decision-making abilities and clinical trial accrual in minority adolescents and adults  with cancer to effectively translate discoveries and improve equity of survival in this underserved population, which is a top priority for the National Cancer Institute and the Institute of Medicine. A future project will be  innovative as it will use Dissemination and Implementation Science methodology to bridge the gap between research and practice.  The supportive research environment at UCSD, the access to a large population of Hispanic adolescents at Rady and adults at UCSD, the expertise and commitment of our team will ensure the successful completion of future projects. Knowledge gained will help to a) inform clinical care and b) design a Hybrid Trial Type 1 study, which will be tested in a larger sample of Hispanics (adolescents and adults) in a future multi-site study. ",Yes,"Yes, if the navigation intervention is effective, this could be translated to bedside care. Knowledge gained will  inform clinical care",yes,Yes,Yes,Yes,"Missing Cancer Control and Population Sciences, Disparities & Community Engagement in the MCC list.    Funding:  NCI Mentored Clinical Scientist Research Career Development Award to Promote Faculty Diversity in Biomedical Research (K08CA230306)   (Aristizabal, 9.0 CM)                                                $1,190,451                                            7/1/2018 - 6/30/2023  ""COMPRENDO: Adaptation and Implementation of a Peer-Navigation Intervention to Improve Research Literacy and Diversity in Pediatric Leukemia Clinical Trials"".   The goal of this study is to improve research literacy in parents of children with leukemia, by adapting, implementing and pilot-testing a culturally and linguistically tailored peer-navigation intervention.    NIH/NCI 1R01CA248439-01A1   (Wolfson)              $2,842,545                                      03/24/2021-3/23/2026                                                                                    Predictors of Systemic Exposure to Oral 6MP during Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.   This study investigates adherence to oral therapy and host polymorphisms to understand the causes of disparities in this population.  Role: Site PI, 0.3 CM    Padres Pedal the Cause   (Su, Aristizabal (0.1 C)         $125,000                                     01/01/2022-12/31/2022                                                                                    Evaluation of a Technology Assisted Intervention for Tailoring Oncofertility Care in   Female Cancer Survivors: A Pilot Cluster Randomized Controlled Trial  This study investigates effectiveness and implementation outcomes of an innovative oncofertility intervention.    American Cancer Society  (Kazak)                             $1,638,000                                     01/01/2020- 6/30/2023                                                                ""Implementing Family Psychosocial Risk Screening for Pediatric Health Equity"".   This study investigates the implementation of the psychosocial assessment score in a multicenter study.   Role: Site PI, non-salary    UC San Diego School of Medicine Summer Research Grant (Banerjee)  $5,000          6/01/2021-9/6/2021  ""Food insecurity in children with Sickle Cell Disease or Hemophilia and their families"".   The purpose of this award is to study food insecurity and household material hardship in children with sickle cell anemia and hemophilia and their families.   Role: Mentor to Shreya Banerjee, University of California San Diego medical student, non-salary     UC San Diego Moores Cancer Center Summer Research Grant (Bird)  $5,000          6/01/2021-9/6/2021  ""Health literacy among caregivers of children with cancer and survivors"".   The purpose of this award is to study health literacy in  parents of children with newly diagnosed cancer and childhood cancer survivors.   Role: Mentor to Victoria Bird, University of California San Diego medical student, non-salary     UC San Diego Moores Cancer Center/San Diego State University Partnership U54 Summer Research Grant (Phan)  $5,000          6/01/2021-9/6/2021  ""Barriers and facilitators to informed consent for pediatric cancer clinical trials: Parents' perspectives"".   The purpose of this award is to study barriers and facilitators to adequate informed consent for therapeutic clinical trials in parents of children with newly diagnosed cancer.   Role: Mentor to Nikki Phan, San Diego State University student, non-salary     Rady Children's Hospital Physician Development Fund Award    (Aristizabal)                                                                                            $5,000        10/01/2019-10/31/2022  ""Delivery of informed consent curriculum for pediatric hematology/oncology fellows to enhance communication skills"".   The purpose of this award is to deliver an informed consent curriculum for pediatric hematology/ oncology fellows to enhance communication skills.  Non-salary    Sanofi-Espoir Foundation (Rivera, Aristizabal)          $100,000                                       6/01/2019-12/31/2021  ""PACARSS: Establishment of a Pediatric and Adolescent Cancer Registry-Surveillance System in Mexico"". The purpose of this project is to implement a pediatric cancer surveillance system in Tijuana, Mexico.   Non-salary    UC San Diego Hispanic Center of Excellence Grant (Rocha)  $4,000                            6/01/2019-12/31/2021  ""Food insecurity and household material hardship in families of children with newly-diagnosed cancer"".   The purpose of this award is to study food insecurity and household material hardship in children with newly- diagnosed cancer and their families.   Role: Mentor to Carolyn Rocha, University of California San Diego, non-salary     Sanofi-Espoir Foundation (Ramirez, Aristizabal)                     $320,000                          6/01/2016-12/31/2021  ""Developing and pilot-testing a tool for early detection of cancer in pediatric oncology"".   The purpose of this project is to develop and pilot-test a tool to improve early detection of pediatric cancer cases in Colombia.   Non-salary                Rady Children's Hospital International Outreach Program   (Aristizabal, 1.0 CM)                                                $300,000 /year                                     11/1/2008-Indefenite                                                  ""Establishing a ""Twinning"" program in pediatric oncology in Baja California, Mexico"".   The purpose of this project is to establish and sustain a pediatric oncology program in Tijuana, Mexico using an implementation framework .                                                                                                          UCSD Clinical Translational Research Institute Pilot Grant (Su)  $20,000                 6/01/2020-10/01/2020  ""Developing a multicomponent implementation strategy for fertility care for female adolescent and young adult cancer survivors.""   The purpose of this award is to develop an implementation strategy to improve onco-fertility care.  Role: Co-I, non-salary    National Institutes of Health, Grant TL1TR001443   CTRI UC San Diego Research Summer Grant (Rocha)                $5,000                             6/01/2019-9/01/2019  ""Food insecurity and household material hardship in families of children with newly-diagnosed cancer"".   The purpose of this award is to study food insecurity and household material hardship in children with newly- diagnosed cancer and their families.   Role: Mentor to Carolyn Rocha, University of California San Diego, non-salary    ",True,Accepted,10.1200/EDBK_320499,Accepted,10.1001/jamanetworkopen.2021.9038,Accepted,10.1002/pbc.28296
32,38.0,Progress Report #1,,,,,,,,,,,,,,,The findings will be presented in national/international meetings this year after the manuscript have been submitted.,"The project that was funded by the PTC has generated excellent and interesting data which are leading to 2 manuscripts. In addition, the follow up work from this project has translational potential for designing novel immunotherapy.",Yes,True,True,False,False,False,True,False,The findings from this project may enable design of novel immunotherapy to treat brain tumors in children.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH K08CA230164 Mechanisms underlying tissue resident memory cell generation and maintenance,825000.0,,,,,,,,,,,,,Yes,"The additional funding will be used to translate the findings from this project to designing immunotherapy for pediatric patients with brain tumors. Firstly, the findings will be validated by completing additional analysis of the same patient samples to confirm T cell reactivities. Then patient-specific vaccines can be produced which can be further tested in a clinical trial.",Yes,Clinical trial to test patient-specific vaccines for brain tumor treatment.,I am participating as a volunteer this year.  ,No,No,,Thank you to Pedal The Cause for supporting research to improve the health of the community and beat cancer.,True,In progress,,In progress,,,
33,39.0,Progress Report #1,Published,10.1200/JCO.2021.39.15_suppl.2615,Submitted,,Submitted,,Submitted,,Submitted,,In progress,,In progress,,"Miller, A.M., Kosaloglu-Yalcin, Z,, Sternberg, L., Montero, L., Bahmanof, M., Frentzen, A., Premlal, A., Greenbaum, J., Seumois, G., Habbaba, R., Natsuhara, A., McConnell, K., Eng, E.,  Sette, A., Peters, B., Schoenberger, S.P., and  Cohen, E.E.W. (2021). A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.. Journal of Clinical Oncology. 39. 2615-2615.          Kosaloglu-Yalin Z., Lee, J., Nielsen, M., Greenbaum, J., Schoenberger, S.P., Miller, A.M., Kim, Y.J., Setter, A., and Peters, B. (2022) Combined assessment of MHC binding and antigen expression improves T cell epitope predictions, iScience doi: 10.1016/j.isci.2022.103850.          Brightman, S.E., Naradikian, M.S., Miller, A.M., and Schoenberger, S.P. (2020) Harnessing neoantigen-specific CD4 T cells for cancer immunotherapy. Journal Leukoc Biol DOI: 10.1002/JLB.5RI0220-603RR.          Shankara Narayanan, J.S., Ray, P., Hayashi, T., Whisenant, T.C., Carson, D.A., Miller, A.M., Schoenberger, S.P., White, R.R. (2019) Irreversible electroporation combined with checkpoint blockade and Toll-like Receptor 7 induced anti-tumor immunity in a murine pancreatic cancer model, Cancer Immunology Research 7: 1714-1726.          Miller, A.M., Kosaloglu-Yalcin, Z., Sternberg, L., Montero, L., Bahmanof, M., Frentzen, A., Lanka, M., Premlal, A., Seumois, G., Greenbaum, J., Makani, S., Lippman, S., Cohen, E.E.W., Peters, B., and Schoenberger, S. P. (2021) A functional neoantigen identification platform reveals frequent spontaneous T cell responses in patients with low mutational burden tumors, submitted and in revision.          Brightman, S.E., Thota, R.R., Becker, A., Naradikian, M.S., Montero, S., Bahmanof, M., Premlal, A., Greenbaum, J.A., Peter, B, Cohen, E.E.W., Miller, A.M. and Schoenberger, S.P. (2022) Recognition of HPV-16 E6-derived epitopes by CD8+ and CD4+ tumor-infiltrating lymphocytes reveals selective presentation of endogenous antigen by MHC-II+ tumor cells.  Submitted.          Dolina, J., Lee, J., Brightman, S., Kosaloglu-Yalcin, Z., Rukman, T., Hall, S., Ramamoorthy-Premlal, A., Greenbaum, J., Maraes, V., Feei-Run, C., Miller, A.M., Cohen, E.E.W., Peters, B. and Schoenberger, S.P. (2021) Therapeutic neoantigen vaccination requires linked CD4+ T cell help, submitted.           Naradikian, M.S., Brightman, S.E., Montero, L., Thota, R.R., Hall, S., Frentzen, A., Kosaloglu-Yalcin, Z., Westernberg, L., Peters, B., Schoenberger, S.P., and Miller, A.M. Engineered T cells targeting the neoantigen, RPS2 V205I, control patient-derived HNSCC xenograft, but only after reintroduction of restricting HLA-B*07:02 allele, in preparation ",We executed a contract with Fresh Wind Bio to support the neoantigen tumor infiltrating lymphocyte program,Yes,True,False,False,False,False,False,False,We expect to improve outcomes in cancer patients across a wide variety of tumors. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,Philanthropic award,750000.0,,,,,,,,,,,,,Yes,"Additional funding will help execute current clinical trial, develop the nanoparticle vaccine platform, and initiate other clinical trials.",Yes,Please see above,Rider,Yes,Yes,Yes,Thank you!!! ,True,Published,10.1016/j.isci.2022.103850,Published,10.1158/2326-6066.CIR-19-0101,Published,10.1002/JLB.5RI0220-603RR
34,40.0,Progress Report #1,,,,,,,,,,,,,,,"Abstracts presented:  1) Shatsky R et al, San Antonio Breast CAncer Symposium December 2019  2) Shatksy R et al, AACR, 2021",Funds provided to conduct clinical trial and to obtain tumor biopsies on enrolled patients,Yes,False,False,False,False,False,True,False,"POTENTIAL activity in breast cancer is the health gain.  Further study will be required to determine if there is health gain. If proven to have additive activity to chemo in metastatic breast cancer, cirmtuzumab could be a treatment option for breast cancer patients.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,"Yes, I have participated.  The participatory experience was incredibly inspirational.  ",Yes,No,,It has been a privilege to collaborate with Padres Pedal the Cause.,True,In progress,,In progress,,,
35,41.0,Progress Report #1,,,,,,,,,,,,,,,None,"In July of 2018, The Life Raft Group brought together a team of pediatric & SDH-deficient GIST experts for a symposium focused on this rare subset of GIST patients. This gathering culminated in the creation of a collaboration of U.S. and international specialists and patient advocates committed to accelerating research, creating guidelines, developing, and expanding clinical trials, and involving patient advocacy groups in this effort to find a cure and improve the quality of life for these patients. Two months later at the Biden Cancer Summit in September 2018, as one of ten featured speakers was the Life Raft Group's Executive Director, Norman Scherzer. He presented the mission and goals of the newly formed Pediatric & SDH-Deficient GIST Consortium. Supported by patient advocates, the collaborative met regularly and ultimately submitted an NIH proposal. Meanwhile, the UC San Diego team applied for funding via the FDA Office of Orphan Products Development (OOPD) and opened the Phase II Study of Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient GIST. Moreover, via the Consortium and patient advocates (Life Raft Group and SDH Research Advocates), we continued to collect SDH tumor tissue from recent operations around the U.S. to further study the biology of SDH-deficient GIST. Via the Consortium, we were ultimately able to open the FDA-funded trial at additional trial sites in the Northeast, Southeast, and Northwest to increase patient access to this trial. Finally, based upon funding from the PTC and FDA, we are now investigating combination therapies in the laboratory as the future extension of this work to improve outcomes in patients with SDH-deficient GIST, with plans to submit an NIH U01 proposal in 2022.",Yes,True,False,False,False,False,False,False,Novel therapy for patients with SDH-def GIST.,Yes,False,True,False,False,False,False,False,Potential to influence NCCN guidelines.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,FDA,1500000.0,Awarded,Phase One Foundation,500000.0,,,,,,,,,,Yes,The TMZ trial is quite costly. Additional funding would aid with completion of enrollement to ultimately avoid early termination due to lack of funding in light of the positive treatment signal for a disease without additional options.,Yes,see above,Rider and Virtual rider.  Awesome experience!!!!,No,Yes,Yes,Thank you for your support!,True,Accepted,10.1158/1078-0432.CCR-21-2092,In progress,10.1007/s10555-019-09818-0,In progress,
36,42.0,Progress Report #1,,,,,,,,,,,,,,,"34.Shaya J, Xie W, Saraiya B, Parikh M, Folefac E, Olson AC, Choudhury AD, Einstein DJ, Heath EI, Parikh RA, Kunos C, Ivy SP, LoRusso P, Kurzrock R, Shapiro G, McKay RR. A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. Poster presentation at Genitourinary Cancer Symposium, February 2021.    McKay et al. Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE). Genitourinary Cancers Symposium. Abstract Presentation. 2022",Received UM1 supplement through DF/HCC to support sequencing for the project. ,Yes,False,False,False,False,False,True,False,This study is testing the combination of radium + olaparib in men with prostate cancer. The phase 1 is complete and RP2D established. Phase 2 is currently underway.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,False,False,False,False,False,True,False,Study made available through the entire ETCTN network for patients across US.,One,Awarded,NCI,200000.0,,,,,,,,,,,,,Yes,Additional funding would help support the expanding biomarker work for this project including tissue sequencing and profiling. ,Yes,The study is currently in phase 2. ,Runner ,No,Yes,No,,True,,,,,,
37,43.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,Knowledge about additional opportunities for treatment in lung cancer.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,False,False,False,True,False,False,False,provide an opportunity for access to medicines across socioeconomic strata.,No additional funding sources,,,,,,,,,,,,,,,,Yes,Continue to fund translational work on clinical trial.,Yes,The work is current at clinical stages but additional support would help to retain staff on project.,virtual rider,Yes,Yes,Yes,appreciate the support to help fund the development of our clinical trial and resources to bring discoveries to the clinic.,True,In progress,,,,,
38,44.0,Progress Report #1,,,,,,,,,,,,,,,,"NIH 1R01 CA254268-01A1 (PI: 12/15/2020-12/14/2025, total award $1,480,000)  Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer  ",Yes,True,False,False,False,False,True,False,I am confident that this research will lead to a series of clinical trials that will expand the use of this ablative therapy (in combination with immunotherapy) for patients with locally advanced pancreatic cancer.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,NIH 1R01CA254268-01A1  (Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer),1480000.0,Submitted,NIH (SPORE) Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer,11000000.0,,,,,,,,,,Yes,"If the SPORE is not funded, we could will need funding to support the clinical trial!",Yes,As above.  We have commitment for drug but need funding to cover costs of clinical trial infrastructure and correlative studies. ,Every year since 2016 (except when you didn't have it due to COVID)!,No,No,,Thank you for the support!,True,Published, 10.1158/2326-6066.CIR-19-0101,In progress,,,
39,45.0,Progress Report #1,,,,,,,,,,,,,,,"Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L  Anagha Deshpande, PhD, Benson Chen, Parham Ramezani-Rad, PhD, Alessandro Pastore, Luyi Zhao, M.S., Oliver Weigert, MD, Scott A. Armstrong, MD PhD, Robert C Rickert, PhD, Bing Ren, Aniruddha J. Deshpande, PhD    Blood (2018) 132 (Supplement 1): 2839.    https://doi.org/10.1182/blood-2018-99-115475",Our lab received 4 year of funding (Research Scholar Award) from the American Cancer Society for this research.,Yes,False,False,False,False,False,True,False,Our studies will earmark B-cell lymphomas with MYC overexpression as candidates for anti-DOT1l therapeutics. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,American Cancer Society ,660000.0,,,,,,,,,,,,,No,,No,,"yes, I have participated in Pedal the Cause and I continue to encourage my lab to do so. ",No,No,,,True,In progress,https://doi.org/10.1182/blood-2018-99-115475,,,,
40,46.0,Progress Report #1,Published,DOI: 10.1371/journal.pbio.3000434,Published,,,,,,,,,,,,"Experimental Biology 2019: GPCRs as novel therapeutic targets for pancreatic cancer    Discovery on Target: Innovation In Targeting Membrane Proteins  2019: GPCRomics: ""New"" GPCRs that expand their utility as drug targets      ",none,Yes,True,False,False,False,False,True,False,The work provided initial validation of GPR68 as a new potential target for pancreatic ductal adenocarcinoma (PDAC) and initiated efforts to identify drugs that might block GPR68 and that might be beneficial for PDAC patients.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,Pfizer CTI; GPR68: A novel drug target for pancreatic ductal adenocarcinoma (PDAC),250000.0,Awarded,NIH R03TR003639 Nanobody inhibitors of proton-sensing G protein-coupled receptors,100000.0,,,,,,,,,,Yes,Increase knowledge regarding actions of GPR68 in pancreatic cancer plus seek to identify and validate nanobodies as novel therapeutics to treat pancreatic cancer.,Yes,The further assessment of GPR68 actions would assess KPC mice (which spontaneously develop pancreatic cancer) with a knockout of GPR68 and determine impact of knockout of GPR68 on growth and progression of pancreatic cancer. Success in those studies (which we find in preliminary studies) would be followed by  assessment of compounds or nanobodies that blunt GPR68 action as a proof-of-concept prior to initiation of clinical assessment of such compounds and/or nanobodies.,Family and person health issues have prevented me from participating other than as a donor.,Yes,No,,,True,Published,doi: 10.3390/ijms20030559,Published,DOI: 10.1016/j.tips.2019.04.001,Published,doi: 10.3389/fphar.2018.00431
41,48.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Three,Awarded,"NCI R01CA174869 ""Regulation of Tumor Invasion and Metastasis by Matrix Stiffness""",1818865.0,Awarded,"1R01CA262794-01A1 ""EPHA2 Receptor Signaling in Breast Cancer Mechanotransduction""",1449402.0,Awarded,AACR/Targeting EPHA2/LYN mechanotransduction to inhibit breast cancer metastasis,50000.0,,,,,,,Yes,The additional fund could help us to explore the translational potentail of the proposed research.,Yes,Testing the targeted therapy in human breast cancer PDX models,"Yes, I have been a rider for 25mile rider, a virtual rider, a volunteer and a cheerleader for my daughter who participated the kid's ride.",No,No,,Thank you so much for your support.,True,Accepted,10.1016/j.devcel.2020.05.031,,,,
42,49.0,Progress Report #1,Accepted,10.1016/j.jbc.2021.100493,Accepted,10.1016/j.isci.2021.102035,Submitted,,Submitted,,In progress,,In progress,,In progress,,,,Yes,True,False,False,True,True,True,False,One of the studies showed the harmful effects of e cigarettes on the gut lining. another pinpointed the impact of barrier protective therapeutics in IBD. ,Yes,False,False,False,True,False,False,False,E cigarette related policies,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,NIH NCATS UG3TR002968 Network-Based Novel Therapeutics in Colorectal Cancers,820000.0,Awarded,NIH NCATS UG3TR003355 Precision therapeutics of inflammatory bowel disease guided by Boolean logic,890000.0,,,,,,,,,,Yes,we have 2 new directions that have emerged from the studies. these could be developed into bigger programs. ,Yes,targets discovered in the studies could be developed into clinical trials,i have donated money.,No,No,,,True,Accepted,10.26508/lsa.201900481,Accepted,10.1038/s41467-021-24470-5,Accepted,10.1016/bs.acr.2021.02.005
43,50.0,Progress Report #1,,,,,,,,,,,,,,,"presentations:  Generation of brain cancer avatars through genome engineering of human iPSCs. SNOG-FiBTRA Symposium ""Multidisciplinary Neuro-Oncology invited speaker: Tampere, Finland, 2022.    Generation of brain cancer avatars through genome engineering of human iPSCs. UCSD Neurosurgery Grand Rounds invited speaker, La Jolla, CA 2021    Generation of brain cancer avatars through genome engineering of human iPSCs. Lady Davis Institute-Jewish General Hospital Joint Cancer-MRM Seminar Series: Montreal, 2021. virtual  ",,Yes,False,False,False,False,False,True,False,"From the human isogenic ATRT models we have generated, we will be able to perform genetic and small molecule screens geared towards identifying therapies that overcome stalled differentiation of these tumors. ",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"Absolutely.  With our ATRT models in hand, successfully generated due to the generosity of Pedal the Cause, we are poised to begin a sophisticated CRISPR screen to identify  drug targets that overcome stalled differentiation.  I currently have 1 graduate student on this project, and additional scientist (postdoc) is warranted to accelerate the generation of results.  ",Yes,"If the next phase of our program identifies a drug that promotes terminal differentiation of ATRT, we could partner with Rady Children's Hospital to bring our results to the clinic.","Yes, in November 2017 my lab and I participated as riders.  It was an incredible event to see the San Diego community come together to support cancer research and treatment.  i look forward to doing it again.",No,No,,,True,Accepted,10.1101/gad.339978.120,,,,
44,51.0,Progress Report #1,,,,,,,,,,,,,,,"1.Geron I, Savino AM, Fishman H, Tal N, Brown J, Turati VA, James C, Sarno J, Hameiri-Grossman M, Lee Y N, Rein A, Maniriho H, Birger Y, Zemlyansky A, Muler I, Davis KL, Marcu-Malina V, Mattson N, Parnas O, Wagener R, Fischer U, Barata JT, Jamieson CHM, Muschen M, Chen C-W, Borkhardt A, Kirsch IR, Nagler A, Enver T, Izraeli S. An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia. Nat Commun. 2022 Feb 03; 13:659    2.R Majeti, C Jamieson, WW Pang, S Jaiswal, NJ Leeper, G Wernig, Weissman IL. Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells. Annual Review of Medicine. 2022 Jan 27; 73: 307-320  3.Ladel L, Jamieson CHM. Upping the antizyme: AZIN1 directs stem cell fate. Blood. 2021 Nov 18; 138(20):1910-1911. PMID: 34792575; PMCID: PMC8602934.  4.Mondala P, Ashni A. Vora AA, Zhou T, Lazzari E, Ladel L, Luo X, Kim Y, Costello C, MacLeod AR*, Jamieson CHM*, Crews LA*.  Selective Antisense Oligonucleotide Inhibition of Human IRF4 Prevents Malignant Myeloma Regeneration via Cell Cycle Disruption.  Cell Stem Cell. 2021 April 1; 28(4):623-626. doi: 10.1016/j.stem.2020.12.017. PMID: 33476575 *co-corresponding authors, contributed to Phase 1 clinical trial development  5.Jiang Q*, Isquith J*, Ladel L, Mark A, Holm F, Mason C, He Y, Mondala P, Oliver I, Reynoso E, Ma W, Ali S, Jamieson Morris I, Diep R, Pham J, Nasamran C, Xu G, Sasik R, Rosenthal SB, Birmingham A, Coso S, Pineda G, Crews L, Donohoe M, Venter JC, Whisenant T, Mesa RA, Alexandrov LB, Fisch KM, Jamieson C. Inflammation Driven Deaminase Deregulation Fuels Human Pre-leukemia Stem Cell Evolution. Cell Reports. 2021. 34(4). DOI: 10.1016/j.celrep.2020.108670  *contributed equally  6.Chan WC, La Clair JJ, Leon B, Trieger KA, Slagt MQ, Verhaar MT, Bachera DU, Rispens MT, Hofman RM, de Boer VL, van der Hulst R, Bus R, Hiemstra P, Neville ML, Mandla KA, Figueroa JS, Jamieson C, Burkart MD.  Scalable Synthesis of 17S-FD-895 Expands the Structural Understanding of Splice Modulatory Activity.  Cell Reports Physical Science. 2020 Dec;1(12): 1-8, contributed to successful pre-IND meeting (PIND153126)  7.Jamieson C,  Martinelli G,  Papayannidis C,  Cortes JE. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. Blood Cancer Discov.  2020 Sept; 1 (2):134-145. DOI:10.1158/2643-3230.BCD-20-0007  8.Chua BA, Van Der Werf I, Jamieson C, Signer RAJ. Post-Transcriptional Regulation of Homeostatic, Stressed, and Malignant Stem Cells. Cell Stem Cell. 2020 Feb 6;26(2):138-159. doi: 10.1016/j.stem.2020.01.005. PMID: 32032524; PMCID: PMC7158223.  9.Van Der Werf I, Jamieson C. The Yin and Yang of RNA Methylation: An Imbalance of Erasers Enhances Sensitivity to FTO Demethylase Small-Molecule Targeting in Leukemia Stem Cells. Cancer Cell. 2019 Apr 15;35(4):540-541. doi: 10.1016/j.ccell.2019.03.011.PMID: 30991023   10.Jiang Q, Isquith J, Zipeto MA, Diep RH, Pham J, Delos Santos N, Reynoso E, Chau J, Leu H, Lazzari E, Melese E, Ma W, Fang R, Minden M, Morris S, Ren B, Pineda G, Holm F, Jamieson C. Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. Cancer Cell. 2019 Jan 14;35(1):81-94.e7. doi: 10.1016/j.ccell.2018.11.017. Epub 2019 Jan 3.PMID: 30612940",Rell Sunn Award  Plenary Talk at AACR 2022  NASA grant    ,Yes,True,True,True,True,True,True,True,We have identified a new method to ,Yes,False,False,False,False,True,False,False,Adding genomics to the EMR in Epic.,Yes,False,False,False,False,False,True,False,More effective therapies and predictive diagnostics.,Yes,False,False,False,False,False,True,False,Understanding ethnic and gender-related differences in patient related splicing and RNA editing as well as APOBEC3 activation will help to improve administration of ADAR1 and APOBEC3 targeted therapies as well as inform the mutagenic potential of lentiviral gene therapy strategies that are used for URM patients ie with sickle cell anemia.,Three,Awarded,LLS,600000.0,Awarded,NASA,2000000.0,Awarded,NIDDK RO1,1000000.0,,,,,,,Yes,We would develop biomarkers for use in pediatric clinical trials focusing on ADAR1 and splicing modulation with Rebecsinib.,Yes,"It would help with development of Rebecsinib, a splicing modulator, for pediatric patients with relapsed/refractory acute leukemia.",Yes as a rider.,Yes,Yes,Yes,Thank you.,True,,,,,,
45,52.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,The knowledge gained from this project will enable a better understanding of the molecular basis for different subtypes of leukemia and could eventually lead to new therapies that are specific to certain subtypes.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Additional funding would enable the continued collection of patient samples from RCHSD and would allow expansion of our study to additional leukemia types beyond B-ALL (for which we currently have the most samples).,No,,"Yes. I have participated as a rider every year since 2016, with the exception of last year during the pandemic when I participated as a virtual rider.",No,No,,,True,Accepted,doi.org/10.1093/nar/gkab621,In progress,,,
46,53.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,Prognostic biomarkers for B-ALL help patients to know the severity of the disease.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,R01 GM138385 - Annotation of cell types in human colon tissue using Boolean analysis,1420781.0,Awarded,R01AI155696 Macrophage Polarization in Response to Infections and Inflammation,1906469.0,,,,,,,,,,Yes,Additional funding will support collection of additional B-ALL samples for a strong prospective analysis.,Yes,Develop a new at home kits for biomarker testing conveniently.,As a Rider,No,No,,,True,In progress,,,,,
47,54.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,TRDRP/Targe5ng invadopodia to prevent head and neck cancer metastasis,500000.0,,,,,,,,,,,,,Yes,We would use the fund to uncover novel components of the pathway.,Yes,We would test the potential of PDGFRa in serving as a prognosis marker of Ewing's sarcoma invasion and metastasis.,I had a great time riding the 25mile ride along the Silver Strand.,No,No,,,True,Published,10.1002/pbc.26721,,,,
48,55.0,Progress Report #1,,,,,,,,,,,,,,,"     Gutierrez J, Flynn S, Huo Y, Lesperance J, Zage PE.  Inhibition of RET via BLU-667 in an in vitro model of neuroblastoma.  Accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, April 2020    Gutierrez J, Flynn S, Zage PE.  Inhibition of RET via BLU-667 in an in vitro Model of Neuroblastoma. Presented at the SACNAS National Diversity in STEM Conference, Long Beach, CA, October 2019         Flynn S, Lesperance J, Phanhthilath N, Paul MR, Zage P.  Dual Target Inhibition of RET and the RAS-MAPK Pathway with RXDX-105 as a Novel Therapeutic in Neuroblastoma.  Presented at the Academic Surgical Congress Annual Meeting, Houston, TX, Feb 2019.    Flynn S, Zage PE.  Evaluation of the multikinase inhibitor RXDX-105 targeting RET and BRAF as a novel therapeutic in Neuroblastoma.  Presented at the Advances in Neuroblastoma Research Conference, San Francisco, CA, May 2018.         Subramonian D, Mo Q, Huang S, Zage P.  Effects of the Multi-Kinase Inhibitor Regorafenib in Neuroblastoma.  Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2017.  J Clin Oncol 2017; 35: 10553.         Subramonian D, Mo Q, Huang S, Zage P.  Effects of the Multi kinase Inhibitor Regorafenib in Neuroblastoma in vitro.  Presented at the 8th Annual Rady Children's Hospital Pediatrics Research Symposium, January 13th, 2017",,Yes,True,False,False,False,False,False,False,     We expect our results will support the use of tyrosine kinase inhibitors with 13-cis-retinoic acid as a well-tolerated therapeutic option for all patients with relapsed or refractory neuroblastoma worldwide and lead to additional international clinical trials to evaluate the efficacy of these combinations as a component of standard neuroblastoma therapy.,No,False,False,False,False,False,False,False,,Yes,False,True,False,False,False,False,False,"     The combination of tyrosine kinase inhibitors with 13-cis-retinoic acid as a therapeutic option for patients with relapsed or refractory neuroblastoma represents a lower cost, outpatient therapy to reduce the overall cost of treatment for children with neuroblastoma",No,False,False,False,False,False,False,False,,Five,Awarded,Hyundai Hope on Wheels,300000.0,Awarded,Bayer Pharma AG,100000.0,Awarded,"Exelixis, Inc",265000.0,Awarded,UCSD Department of Pediatrics Pilot Grant,50000.0,Moores Cancer Center Support Grant Pilot Project Award,Awarded,50000.0,Yes,"     Additional funding support would allow us to pursue studies to further identify and validate signaling pathways in neuroblastoma preclinical models, to further pursue the functional significance of novel intracellular signaling pathways in pediatric tumor development, growth, and spread and in neuroblastoma resistance to retinoic acid therapy, and to identify novel candidate targets for therapies.",Yes,"     Additional funding support would allow us to identify candidate therapeutic targets that could be evaluated, and agents directed against these targets could be developed as candidate therapies, eventually leading to animal studies and early phase clinical trials to evaluate the safety and efficacy of these agents in children with cancer.  Additional funding would also allow us to develop early phase clinical trials to evaluate the safety and efficacy of combinations of existing, currently available kinase inhibitors with 13-cis-retinoic acid for patients with relapsed or refractory neuroblastoma as well as clinical trials in children with other types of cancer, leading to expanded indications for use of these combinations for pediatric cancer treatment.",I have participated as both a virtual participant and as a participant in spin classes at Petco Park,Yes,No,,Funding from Padres Pedal the Cause has been instrumental in building and maintaining my research laboratory and scientific productivity in San Diego and has  been greatly appreciated!,True,Published,,Published,,Submitted,
49,56.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,One,Planned,q3rq3,1.0,,,,,,,,,,,,,,,,,,,,,qwe,True,,,,,,
50,61.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,"This project will define a novel treatment paradigm for HPV- (HPV unrelated/smoking associated) head and neck cancers, and defines a unique understanding of the role of lymphatic drainage in facilitating response to immunologic therapy",No,False,False,False,False,False,False,False,,Yes,True,False,False,False,False,False,False,The treatment paradigm being proposed has the potential to dramatically decrease morbidity of HNSCC treatment,Yes,True,False,False,False,False,False,False,"If successful, this treatment paradigm has the potential to decrease treatment costs, as well as long term functional and financial toxicity for head and neck cancer patients",No additional funding sources,,,,,,,,,,,,,,,,Yes,"To fully develop an analogous concept for HPV positive head and neck cancer, that is one of the fastest growing cancers in the US today",Yes,"The potential for neoadjuvant radiotherapy approaches is perhaps even more dramatic in the context of HPV related cancers, as our preliminary data demonstrate that this approach is more effective in these cancers, dramatically reducing toxicity","Yes, as a participant for the past five years!!",Yes,No,,THANK YOU FOR YOUR SUPPORT!!,True,In progress,,In progress,,,
51,65.0,Progress Report #1,,,,,,,,,,,,,,,none,none,Yes,True,True,True,True,False,True,False,novel therapy for cancer (leukemia),No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,True,True,True,True,False,True,False,People of all backgrounds would benefit equally from this research,No additional funding sources,,,,,,,,,,,,,,,,Yes,Would allow further development of a therapeutic antibody for clinical trial implemention.,Yes,Allow development of a clinical trial.,I was a rider several times in the past. it was a great experience. ,No,No,,,True,,,,,,
52,66.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,"If successful, this project will identify novel targets for the treatment on myeloid malignancies like AML. meanwhile, new tools for the study of the relevant biology are being produced.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"Would have to ask Dr. Reya, but additional funding could help better refine existing tools in development. FOr example, the entire biomarker aim of the original proposal that was not funded could be invigorated with additional funding.",No,,Yes - I have ridden in every Pedal the Cause to date and have led teams in the past.,No,No,,,True,,,,,,
53,67.0,Progress Report #1,,,,,,,,,,,,,,,Preparing for ESMO 2022,,Yes,True,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Yes,False,False,False,False,False,False,False,,One,Planned,,100000.0,,,,,,,,,,,,,Yes,,Yes,,"Yes, virtual rider. Due to COVID there as been a huge disruption to this event, however, virtual participation has definitely lead to more comradery. I look forward to the in person even to feel the energy and make connections. ",Yes,No,,"This pilot funding is extremely helpful to bridge the excellent institutes in southern California. Very difficult, despite our proximity, to connect during COVID especially, but this funding created fantastic relationships, advanced the careers of junior lab members, and helped develop new pathways of science to translate into patient treatment options. ",True,In progress,,In progress,,,
54,68.0,Progress Report #1,,,,,,,,,,,,,,,,,,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,,,,,,,,,,,,,,,,,,,,,,,,,,True,,,,,,
55,69.0,Progress Report #1,,,,,,,,,,,,,,,"Turner MA, Amirfakhri S, Nishino H, Lwin TM, Savides TJ, Reid TR, Singer BB, Hoffman  RM, Bouvet M. A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-  Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent  Antibodies to Carcinoembryonic-Antigen-Related Cell-Adhesion Molecules. In Vivo. 2021 Jul-Aug;35(4):1959-1963. doi: 10.21873/invivo.12463.PMID: 34182469    Turner MA, Amirfakhri S, Lwin TM, Hollandsworth HM, Nishino H, Singer BB, Reid TR, Hoffman RM. Bouvet M. A Novel Imageable Patient-Derived Orthotopic Xenograft Model of Gastroesophageal Junction Adenocarcinoma Targeted with Fluorescent Antibodies to Carcinoembryonic Antigen-Related Cell Adhesion Molecules. Presentation 91. Presented at the Society of Surgical Oncology Meeting, Colorectal Virtual Forum, March 18-19, 2021.","GENOMICALLY SILENT REFRACTORY GASTRIC CANCER OVEREXPRESS CXCL5 (3699974), has been selected for poster presentation during Digestive Disease Week® (DDW) 2022, taking place May 21-24, 2022, at the San Diego Convention Center in San Diego, CA, and online.",Yes,True,True,True,True,True,True,False,The labeling of gastric cancers will provide opportunities for earlier detection and improved surgical resection of gastric cancer.,Yes,True,True,False,False,True,True,False,The development of tumor specific probes for gastric cancer may lead to new clinical guidelines for detection and treatment of gastric cancer.,Yes,True,True,False,False,True,True,False,"If gastric cancer can be detected at an earlier stage, then patient survival will be improved.",No,False,False,False,False,False,False,False,,One,Awarded,"NIH/NCI Bouvet (PI) 1R01CA256973-01A1 ""Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer""",2264206.0,,,,,,,,,,,,,Yes,Additional funding well help establish more mouse models of gastric cancer.,Yes,Additional research will advance the technology into clinical stages.,No.,No,No,,,True,Accepted,10.21873,In progress,,,
56,70.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,"This project was advancing a new kind of cancer therapeutic, specifically performing preclinical testing on a new anti-cancer drug to define the optimal patient subsets within lung cancer",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Identification of additional autophagy inhibitors against other targets could help build a portfolio of therapeutics to use in different cancer subtypes; we are world leaders in this new therapeutic space,Yes,Development of new therapeutics against other components of the autophagy pathway would lead to drugs better suited to individual subsets of cancers,"Yes, I have participated in PPTC the last 3 years (5K run) and will be there on April 9th, 2022. I also spoke from the main stage 3 years ago.",Yes,No,,,True,Published,https://www.biorxiv.org/content/10.1101/2021.05.15. 444304v1,In progress,,,
57,71.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,"This project was advancing a new kind of cancer therapeutic, specifically performing preclinical testing on a new anti-cancer drug to define the optimal patient subsets within lung cancer",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Identification of additional autophagy inhibitors against other targets could help build a portfolio of therapeutics to use in different cancer subtypes; we are world leaders in this new therapeutic space ,Yes,Development of new therapeutics against other components of the autophagy pathway would lead to drugs better suited to individual subsets of cancers ,"Yes, I have rode in PPTC the last 4 years and will ride again on April 9.  Also spoke from the main stage 2 years ago.  ",Yes,No,,,True,Published,10.1021/acs.jmedchem.0c00873,In progress,https://www.biorxiv.org/content/10.1101/2021.05.15.444304v1,,
58,73.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,True,False,True,False,"Our project seeks to establish new ways to ascertain if a particular immune checkpoint blockade  treatment will be effective in treating certain classes of patients.  If successful, we believe that this study can help tailor therapies to individual patients. It might also give us insights into the reasons some treatments are effective while others aren't.  ",Yes,False,False,False,True,False,True,False,Our project could improve guidelines as to how patients are treated with immune checkpoint blockade  treatment. ,Yes,False,False,False,True,False,True,False,"If we can provide a scientific basis for treatment efficacy, it can save patient time and healthcare expenditures by avoiding treatments that are unlikely to be effective and potentially tailor these therapies to individual patients.  ",No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,Not yet,No,No,,,True,,,,,,
59,75.0,Progress Report #1,,,,,,,,,,,,,,,In preparation,Better integration between UCSD and Salk and the MCC biorepository,Yes,False,False,False,False,False,True,False,Pancreatitis biology is poorly understood due to the lack of human models. Furthermore it is unclear how pancreatitis promotes pancreas cancer. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Additional funds would enable our team to continue accruing patients for our study and grow our understanding of inflammation and cancer of the pancreas. ,No,,Not yet due to the pandemic,No,No,,Thank you so much for the support,True,In progress,,,,,
60,76.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,True,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,,Yes,,,No,No,,,False,Published,,In progress,,,
61,77.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,True,True,False,True,False,False,,Yes,True,True,True,False,True,False,False,N/a,Yes,True,True,True,False,True,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,,No,No,,,True,,,,,,
62,78.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,True,False,False,False,False,False,Better surveillance and screening for cardiac function.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,One,Awarded,NIH/NCI,250000.0,,,,,,,,,,,,,No,,No,,,,,,,True,In progress,,,,,
63,82.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,I have participated as a virtual rider.  It is a very exciting event.,Yes,No,,,True,Accepted,10.1186/s13059-022-02640-y.,,,,
64,83.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,"It is our goal to develop novel therapeutics,  but currently this remains work in progress.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH R01CA254397 Mechanism Of Action Of A Novel Golgi-Targeted,3310103.0,,,,,,,,,,,,,Yes,"Development of new direct binding assays,  and synthesis of new molecules to further  explore SAR to produce more potent  compounds with better ADME/PK properties.",Yes,"The goal is to develop compounds that are  attractive for commercialization, to enable  movement toward clinical use.",Yes as a rider,Yes,No,,,True,,,,,,
65,85.0,Progress Report #1,,,,,,,,,,,,,,,None yet,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH,2000000.0,,,,,,,,,,,,,Yes,"We still have few samples profiled, and increased funding would allow us to increase the numbers of patients profiled.",Yes,"We still have few samples profiled, and increased funding would allow us to increase the numbers of patients profiled.",Virtual Rider,No,No,,,True,,,,,,
66,86.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,,No,No,,,True,,,,,,
67,88.0,Progress Report #1,,,,,,,,,,,,,,,"Park S, Rong Z, Williamson L, Luger T, Johnson E, Hartman S, Lindsley C, Sears DD, Bejar R. (2022) Clonal hematopoiesis profiles in breast cancer survivors using error-corrected sequencing. American Association for Cancer Research (AACR) Annual Meeting. April 2022. New Orleans, LA.",,Yes,True,False,False,False,False,False,False,Increased awareness about and magnitude assessment of treatment-enhanced risk for clonal hematopoiesis in breast cancer survivors. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,Myelodysplastic Syndromes Foundation Young Investigator Award to project fellow Dr. Soo Park,100000.0,,,,,,,,,,,,,No,,No,,"Yes, Great event with so much enthusiasm",No,No,,"My Co-PI, Dr. Bejar is the best to contact for more information.",True,In progress,,,,,
68,89.0,Progress Report #1,,,,,,,,,,,,,,,0.0,"We generated a considerable amount of data that was used to support an application for an NIH multi-PI grant, which was funded for 5 years.",Yes,False,False,False,False,False,True,False,We are developing therapeutic targets for anti-cancer drug development.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH R01CA251414- FEN1-Nuclease-Targeted Therapy for Ewing Sarcoma,3000000.0,,,,,,,,,,,,,No,,No,,"No, I have been recovering from brain surgery.  I have made donations.",No,No,,We are very thankful for the funding.  The project is continuing with 5 years of substantial NIH funding.,True,,,,,,
69,90.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,We are hopeful that FEN1 inhibitors could be used to treat Ewing Sarcoma patients and improve survival outcomes. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH RO1 ,3827000.0,,,,,,,,,,,,,Yes,We would expand our in vivo testing with mouse models to test the efficacy of FEN1 inhibitors in xenograft models. ,Yes,If the in vivo studies are promising we could work towards opening phase 1 clinical trials of FEN1 inhibitors in Ewing sarcoma patient. ,,,,,,True,,,,,,
70,92.0,Progress Report #1,,,,,,,,,,,,,,,Two residents presented their data at meetings of the Society for Interventional Oncology,,Yes,True,False,False,False,False,False,False,"If our project is funded and successful, it will change the nutritional recommendations for patients undergoing liver directed therapies ",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Our proposal was highly rated by the NIH but has not received funding as yet.  Additional funding to allow the generation of further preliminary data would be helpful.,Yes,Successful funding of our Liver Cancer clinical trial grant. ,Yes.  Many years.  Was more fun before Padres got involved.  Camping O/N in Temecula was fun.,No,No,,,True,,,,,,
71,93.0,Progress Report #1,,,,,,,,,,,,,,,none,none,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,no,No,No,,no,True,,,,,,
72,94.0,Progress Report #1,Published,10.1016/j.brachy.2021.07.001,,,,,,,,,,,,,"Oral presentations:  1. Kallis, K., Jyoti Mayadev, J., Kisling, K.,  Ray, X., Scanderbeg, D., Brown, D., Moore, K.L.,  Meyers, S.M. Knowledge-Based Models to Predict  Needle Necessity in Cervical Brachytherapy: A Novel  Tool to Assist Physician Decision-Making. 66th  Annual Meeting of the Canadian Organization of  Medical Physicists, Kelowna, Canada, 22-25 June  2021.  2. Cortes, K., Simon, A., Kallis, K., Mayadev,  J., Meyers, S., Moore, K., Knowledge-Based  Three-Dimensional Dose Prediction for  Tandem-And-Ovoid Brachytherapy. Joint AAPM COMP  Virtual Meeting, 12-16 July 2020, p. 53116.  3. Meyers, S.M., Yusufaly, T., Simon, A.,  Covele, B., Brown, D., Scanderbeg, D., Mayadev, J.,  Moore, K. Brachytherapy for Locally Advanced  Cervical Cancer: Using Knowledge-based Models to  Predict Dose to Critical Structures. 65th Annual  Meeting of the Canadian Organization of Medical  Physicists, Kelowna, Canada, 24-27 September 2019.  Poster presentations:  1. Kallis, K., Mayadev, J., Kisling, K., Ray,  X., Scanderbeg, D., Brown, D., Yashar, C., Einck,  J., Mell, L., Simon, A., Moore, K., Meyers, S.  Feasibility of Knowledge-Based Dose Predictions to  Inform Needle Supplementation in Cervical  Brachytherapy. International Journal of Radiation  Oncology Biology Physics 2021;111(3,  Supplement):e136.  2. Kallis, K., Brown, D., Scanderbeg, D.,  Kisling, K., Covele, B., Simon, A., Yashar, C.,  Einck, J., Mell, L., Mayadev, J., Moore, K.,  Meyers, S. Can Knowledge-Based Dose Prediction  Models Inform Brachytherapy Needle Decision-Making  for Cervical Cancer? Joint AAPM COMP Virtual  Meeting, 12-16 July 2020, p. 53379.  3. Kallis, K., Covele, B., Simon, A., Brown,  D., Scanderbeg, D., Kisling, K., Yashar, C., Einck,  J., Mell, L., Mayadev, J., Moore, K., Meyers, S.  What Knowledge-Based Dose Prediction Models Tell Us  About Ovoid Vs. Ring Based Brachytherapy  Applicators. Joint AAPM COMP Virtual Meeting, 12-16  July 2020, p. 53457. (Blue Ribbon Poster)  4. Yusufaly, T., Simon, A., Hild, S., Brown,  D., Scanderbeg, D., Mayadev, J., Moore, K., Meyers,  S.M. A Knowledge-Based Organ Dose Prediction Tool  for Brachytherapy Treatment of Cervical Cancer  Patients. 61st Annual Meeting of the American  Association of Physicists in Medicine, San Antonio,  Texas, 14-18 July 2019.","Using the preliminary data collected with the help of this grant, co-PI Sandra Meyers was able to apply for her NIH K  award and received a very competitive impact score (19).",Yes,True,True,True,False,True,True,False,"The tools developed from this work could result in patient receiving higher quality treatments with reduced toxicity, and reduce the time patients spend under anesthesia (and therefore reduce the  chance of complication)",Yes,True,True,True,False,True,True,False,"These tools can help healthcare professionals with decision-making that impacts the quality and length  of patient treatments, by helping them select appropriate brachytherapy devices to implant",Yes,True,True,True,False,True,True,False,"Automated planning could reduce the time patients spend under anesthesia, which reduces hospital  resource usage and could reduce costs of  brachytherapy procedures",Yes,True,True,True,False,False,False,False,"Currently, under-resourced centers (particularly in developing countries) are not offering brachytherapy, which is partly due to the hospital resources and clinician expertise required for these procedures. The tools developed in this work will improve the ease of this procedure through automation and decision-making guidance, which could allow more centers that lack expertise to offer this very necessary treatment for cervical cancer.",No additional funding sources,,,,,,,,,,,,,,,,Yes,Hire personnel and test the automated brachytherapy treatment planning.,Yes,"Once automated treatment planning has been validated on retrospective data, we will need to perform a pilot study to test its efficacy in the clinic real-time, compared to current manual procedures. This will also allow us to determine whether the automation significantly reduces  procedure time. Funding would allow us to hire personnel to carry out this pilot study.",Participated as a rider before COVID,No,No,,,True,Published,10.1016/j.brachy.2020.04.008,Published,10.1016/j.semradonc.2020.05.009,Published,10.1016/j.brachy.2021.08.010
73,95.0,Progress Report #1,Published,10.1016/j.brachy.2021.07.001,,,,,,,,,,,,,"Oral presentations:  other publications (non-peer reviewed) associated with 1. Kallis, K., Jyoti Mayadev, J., Kisling, K.,  Pedal the Cause support Ray, X., Scanderbeg, D., Brown, D., Moore, K.L.,  Meyers, S.M. Knowledge-Based Models to Predict  Needle Necessity in Cervical Brachytherapy: A Novel  Tool to Assist Physician Decision-Making. 66th  Annual Meeting of the Canadian Organization of  Medical Physicists, Kelowna, Canada, 22-25 June  2021.  2. Cortes, K., Simon, A., Kallis, K., Mayadev,  J., Meyers, S., Moore, K., Knowledge-Based  Three-Dimensional Dose Prediction for  Tandem-And-Ovoid Brachytherapy. Joint AAPM COMP  Virtual Meeting, 12-16 July 2020, p. 53116.  3. Meyers, S.M., Yusufaly, T., Simon, A.,  Covele, B., Brown, D., Scanderbeg, D., Mayadev, J.,  Moore, K. Brachytherapy for Locally Advanced  Cervical Cancer: Using Knowledge-based Models to  Predict Dose to Critical Structures. 65th Annual  Meeting of the Canadian Organization of Medical  Physicists, Kelowna, Canada, 24-27 September 2019.  Poster presentations:  1. Kallis, K., Mayadev, J., Kisling, K., Ray,  X., Scanderbeg, D., Brown, D., Yashar, C., Einck,  J., Mell, L., Simon, A., Moore, K., Meyers, S.  Feasibility of Knowledge-Based Dose Predictions to  Inform Needle Supplementation in Cervical  Brachytherapy. International Journal of Radiation  Oncology Biology Physics 2021;111(3,  Supplement):e136.  2. Kallis, K., Brown, D., Scanderbeg, D.,  Kisling, K., Covele, B., Simon, A., Yashar, C.,  Einck, J., Mell, L., Mayadev, J., Moore, K.,  Meyers, S. Can Knowledge-Based Dose Prediction  Models Inform Brachytherapy Needle Decision-Making  for Cervical Cancer? Joint AAPM COMP Virtual  Meeting, 12-16 July 2020, p. 53379.  3. Kallis, K., Covele, B., Simon, A., Brown,  D., Scanderbeg, D., Kisling, K., Yashar, C., Einck,  J., Mell, L., Mayadev, J., Moore, K., Meyers, S.  What Knowledge-Based Dose Prediction Models Tell Us  About Ovoid Vs. Ring Based Brachytherapy  Applicators. Joint AAPM COMP Virtual Meeting, 12-16  July 2020, p. 53457. (Blue Ribbon Poster)  4. Yusufaly, T., Simon, A., Hild, S., Brown,  D., Scanderbeg, D., Mayadev, J., Moore, K., Meyers,  S.M. A Knowledge-Based Organ Dose Prediction Tool  for Brachytherapy Treatment of Cervical Cancer  Patients. 61st Annual Meeting of the American  Association of Physicists in Medicine, San Antonio,  Texas, 14-18 July 2019.","Dr Meyers  Using the preliminary data collected with the help  the support of Pedal the Cause of this grant, I was able to apply for an NIH K  award and received a very high score. I am still  awaiting confirmation",Yes,True,True,True,False,True,False,False,to implement brachy for cervix cancer ,Yes,True,True,True,True,False,False,False,To make brachy more automated and clinical ,No,False,False,False,False,False,False,False,,Yes,True,True,True,False,False,True,False,Brachytherapy to increase cures in cervix cancer ,No additional funding sources,,,,,,,,,,,,,,,,Yes,To advance treatment planning in cevrical cancer brachytherapy ,Yes,To increase awareness and knowledge ,rider ,No,No,,thank you!,True,Published,10.1016/j.brachy.2020.04.008,Accepted,10.1016/j.semradonc.2020.05.009,Accepted,10.1016/j.brachy.2021.08.010
74,96.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,True,True,False,False,False,False,"As discussed below, this study could lead to re-evaluation of the use of G-CSF for treatment of medulloblastoma patients, and perhaps use of alternative therapies.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"Further funding would allow for additional investigations into the mechanisms by which G-CSF promotes growth of CD114+ medulloblastoma cells, and help identify additional approaches for targeting them.",Yes,"The observation that G-CSF can expand CD114+ medulloblastoma cells could be translated into a trial testing whether this occurs in patients, and could evaluate whether alternatives to G-CSF might be associated with better outcomes.",I have participated as a virtual rider. ,No,No,,"This project was driven by Pete Zage's lab, and further communication would be best directed to him.",True,Published,10.1093/noajnl/vdaa062,,,,
75,98.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,Alex's Lemonade Stand Innovation Award,125000.0,,,,,,,,,,,,,No,,No,,I have participated as a Virtual Rider.,No,No,,,True,,,,,,
76,99.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,New treatment for multiple solid tumors,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,CTI Pfizer-UCSD collaboration,200000.0,,,,,,,,,,,,,No,,No,,No,Yes,No,,It is highly likely that this product will enter clinical trials in the next few years.  Thank you for your help,True,Published,10.7554/eLife.63060,Published,10.1158/1535-7163.MCT-21-0548,,
77,100.0,Progress Report #1,,,,,,,,,,,,,,,,"Project Number:R21 AG068651  Name of PD/PI:Adams, Peter D.  *Source of Support:NIH/NIA  *Primary Place of Performance:Sanford Burnham Prebys Medical Discovery Institute  Project Start/End Date:08/2020 - 05/2022  *Total Award Amount $536,250  ",Yes,True,False,False,False,False,False,False,Our progress towards a screen for modulators of CCF gets us closer to our goal of approaches to promote inflammation and immune surveillance of tumors. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,NIH R21AG058075,536250.0,,,,,,,,,,,,,No,,No,,Yes. I have ridden the century a few times. ,No,No,,"Thanks very much for the funding. This is a basic research project, but the funding was very useful in moving towards our goals and gaining additional funding. ",True,,,,,,
78,101.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,Possible novel therapeutic target in cancer and infectious disease,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Expand the number of samples collected and study blocking antibodies on anti-tumor response,Yes,Continued collaboration support at Dr Linda Bradley's lab with samples from the cutaneous oncology group at MCC,"yes, each year",,,,,True,Submitted,,,,,
79,102.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,"Yes. I have participated as a rider in every Pedal the Cause Event since 2016, with the exception of last year when I was a virtual rider.",No,No,,,True,In progress,,,,,
80,103.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,Development of novel therapeutics for pancreatic cancer,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Perform in vivo studies to identify optimal strategies to target NRF2 related metabolism,Yes,Proof of concept for early Phase clinical trials,Yes- enjoyed immensely,No,No,,No- just thank you for supporting our work,True,Published,https://doi.org/10.1016/j.ccell.2021.02.016,Submitted,,,
81,108.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"We would continue our modeling of the interaction between the microbiome and DNA damage repair proteins in the gut, and how this contributes to tumorigenesis. These are expensive, long-term studies, and pilot funding helps sustain the project until there is sufficient preliminary data for a larger R01-level grant application or for publication.",No,,"Yes, as a volunteer along with all my lab members.",No,No,,,True,,,,,,
82,111.0,Progress Report #1,,,,,,,,,,,,,,,Not applicable,As detailed above,Yes,True,False,False,False,False,False,False,Better understanding the implications of epigenetic changes on cancer progression may help inform novel anti cancer treatment strategies,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Continued exploration of the epigenetic + IO relationship is pivotal as we explore new anti cancer treatment strategies.  Such approaches could include EZH2 inhibition + IO,No,,"Yes, as a rider and it is always a transformational experience. I love it!",No,No,,,True,In progress,,,,,
83,112.0,Progress Report #1,Published,Please see Dr. Aristizabal's report,Published,Please see Dr. Aristizabal's report,Published,Please see Dr. Aristizabal's report,Published,Please see Dr. Aristizabal's report,Published,Please see Dr. Aristizabal's reprot,Published,Please see Dr. Aristizabal's reprot,Published,Please see Dr. Aristizabal's reprot,None.  Dr. Aristizabal has presented on behalf of the team.,None.  Dr. Aristizabal has presented on behalf of the team.,Yes,False,True,True,True,True,True,True,"Findings could potentially benefit parents' experience, satisfaction, decision-making abilities and comprehension of informed consent in parents of children with cancer participating in therapeutic clinical trials. This intervention will also contribute to reduce disparities in underserved populations.",Yes,False,True,True,True,True,True,True,The navigator intervention could potentially be translated to bedside clinical care and thus be included in training for all providers involved in informed consent processes for therapeutic and non-therapeutic clinical trials. Results can also be translated to adolescents and adults with cancer. ,Yes,False,True,True,True,True,True,True,"The navigator intervention could potentially increase clinical trials accrual and benefit more patients by providing equal access.  By increasing minority participation in clinical trials, we can effectively and equally translate discoveries and treatment benefits. Our results will inform clinical care and the design of a multi-site randomized clinical trial in a larger sample.",Yes,False,True,True,True,True,True,True,"The navigator intervention could potentially increase clinical trials recruitment specifically in populations experiencing disparities. By increasing minority participation in clinical trials, we can effectively and equally translate discoveries and treatment benefits.",No additional funding sources,,,,,,,,,,,,,,,,Yes,"Future Curebound funding will be critical to expand improvements in decision-making abilities and clinical trial accrual in minority adolescents and adults  with cancer to effectively translate discoveries and improve equity of survival in this underserved population, which is a top priority for the National Cancer Institute and the Institute of Medicine. A future project will be  innovative as it will use Dissemination and Implementation Science methodology to bridge the gap between research and practice.  The supportive research environment at UCSD, the access to a large population of Hispanic adolescents at Rady and adults at UCSD, the expertise and commitment of our team will ensure the successful completion of future projects. Knowledge gained will help to a) inform clinical care and b) design a Hybrid Trial Type 1 study, which will be tested in a larger sample of Hispanics (adolescents and adults) in a future multi-site study. ",Yes,"Yes, if the navigator intervention is effective, this could be translated to bedside care. Knowledge gained will  inform clinical care",Yes,Yes,Yes,Yes,"Please see Dr. Aristizabal's report.  She is the contact person for any outreach, which is why I checked ""no"" above.",True,Published,Please see Dr. Aristizabal's report,Published,Please see Dr. Aristizabal's report,Published,Please see Dr. Aristizabal's report
84,113.0,Progress Report #1,,,,,,,,,,,,,,,The findings will be presented in  other publications (non-peer reviewed) associated with national/international meetings this year after the manuscripts have been submitted.  ,"The project that was funded by PTC has  generated excellent and interesting data which are leading to 2 manuscripts. In addition, the follow up work from this project has translational potential for designing novel immunotherapy.",Yes,True,True,False,False,False,True,False,The findings from this project may enable design of novel immunotherapy to treat brain tumors in children.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,"The additional funding will be used to translate the findings from this project to designing immunotherapy for pediatric patients with brain tumors. Firstly, the findings will be validated by completing additional analysis of the same patient  samples to confirm T cell reactivities. Then  patient-specific vaccines can be produced which can be further tested in a clinical trial.",Yes,Clinical trial to test patient-specific vaccines for brain tumor treatment.,I will volunteer.  ,No,No,,Thank you to Pedal The Cause for supporting research to improve cancer treatment.,True,In progress,,In progress,,,
85,117.0,Progress Report #1,,,,,,,,,,,,,,,I have presented the interim findings of this trial at San Antonio Breast Cancer Symposium Dec 2019 and American Association of Cancer Research April 2021. Both are major international cancer meetings.,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,"Yes I participated in 2018, 2019 and even did a video supporting the cause with my patient (Saundra Pelletier). I had a fantastic experience. ",No,Yes,No,,True,In progress,,,,,
86,118.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,"If this trial meets its endpoint, it will establish a new standard of care therapy for this patient population",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,FDA,499999.0,,,,,,,,,,,,,Yes,Ongoing expansion of the current project,Yes,Planning additional clinical trials of combination therapy,Yes,No,Yes,Yes,,True,Published,10.1158/1078-0432.CCR-21-2092,,,,
87,119.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,True,False,False,False,False,False,"This study will provide information about whether the immune response in prostate cancer patients treated with olaparib in combination with the standard of care, radium-223, for bone metastases may have better anti-tumor activity.",Yes,False,True,False,False,False,False,False,These studies on the immune compartment may lead to support for adjusting clinical treatment guidelines for bone metastatic castration resistant prostate cancer to include the new combination treatment of Ra-223 plus olaparib.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Planned,NIH NCI,2000000.0,,,,,,,,,,,,,Yes,We have established a living cryobank of a time series of patient circulating immune cells treated with DNA damage inducing and amplifying treatments from patients with lethal bone metastatic CRPC. These live cells can be used to define the immune repertoire under these conditions to identify immune therapeutic targets and regimens.,Yes,Further studies on the potential immune potentiation of the combination treatment in this clinical trial may lead to rapid clinical trial with check point inhibitors and novel immunotherapies.,Yes I have been a Virtual Rider and participated in two of the 5k walks. ,No,No,,Pedal the Cause is a unique funding agency in which we get to participate in generating the funding and in generating the research. It is much more meaningful to have such vested interest in and commitment to the hard work and efforts required to carry out cancer research that is clinically meaningful.,True,In progress,,,,,
88,120.0,Progress Report #1,,,,,,,,,,,,,,,I gave at least 2-3 seminars on this topic.,Nothing to add.,Yes,False,False,False,False,False,True,False,Low dose oxaliplatin or mitoxantrone can be combine with PD-(L)1 blocking antibodies to improve response rates to immunotherapy.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,Merck; Using low dose oxaliplatin to augment antigen processing and presentation and renders prostate cancer responsive to checkpoint inhibitors.,565000.0,,,,,,,,,,,,,Yes,Additional funding would allow the initiation of a clinical trial.,Yes,Additional funding would allow the initiation of a clinical trial.,"Yes, as a virtual rider.",No,Yes,Yes,None.,True,Published,0.1073/pnas.2025840118,,,,
89,121.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,True,True,False,False,True,False,Our project has helped to advance clinical evaluation of IRE combination therapies in the treatment of PDAC,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Submitted,"NCI, Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer",2750000.0,,,,,,,,,,,,,Yes,Rebecca White is the principal investigator on the project and would be the logical scientist to provide this information,Yes,To advance a clinical trial in which IRE is combined with a personalized cancer vaccine and CD40 antibody treatment,"Yes, I have been a supporting member of various teams",No,No,,,True,Accepted,10.1158/2326-6066.CIR-19-0101,In progress,,,
90,123.0,Progress Report #1,,,,,,,,,,,,,,,"Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L  Anagha Deshpande, PhD, Benson Chen, Parham Ramezani-Rad, PhD, Alessandro Pastore, Luyi Zhao, M.S., Oliver Weigert, MD, Scott A. Armstrong, MD PhD, Robert C Rickert, PhD, Bing Ren, Aniruddha J. Deshpande, PhD    Blood (2018) 132 (Supplement 1): 2839.",American Society of Hematology Abstract Achievement Award to trainee Anagha Deshpande,Yes,True,False,False,False,False,True,False,These studies may help advance a novel epigenetic therapy in MYC-driven cancers,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Awarded,American Cancer Society ,660000.0,,,,,,,,,,,,,No,,No,,Yes,Yes,No,,,True,In progress,https://doi.org/10.1182/blood-2018-99-115475,,,,
91,124.0,Progress Report #1,,,,,,,,,,,,,,,"S. Wiley, K. Sriram, W. Liang, S. Chang, T. McCann, H. Nishihara, R. French, J. Sicklick, A. Lowy, P.A. Insel. GPR68, a proton sensing GPCR,  mediates pancreatic cancer associated fibroblast-cancer cell interaction and may be a novel therapeutic target for pancreatic cancer. Pharmacology 2017. British Pharmacology Society.(abstract)",,Yes,True,False,False,False,False,False,False,"This award facilitated our discovery that the low pH in pancreatic cancers is ""used"" by tumors for interaction between cancer associated fibroblasts (CAFs) and cancer cells. The cancer cells increase expression of GPR68, a cell surface receptor, on CAFs and in turn, GPR68 on CAFs responds to low pH to produce factors that stimulate cancer cell growth. We identified mechanisms for those actions and also potential GPR68 inhibitors. Such inhibitors may be novel ways to treat pancreatic cancer.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,Donor in all events since inception,No,No,,,True,Published,10.1096/fj.201700834R,Published,10.1124/mol.117.111062,Published,10.3389/fphar.2018.00431
92,125.0,Progress Report #1,,,,,,,,,,,,,,,,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,No,No,No,,"We appreciate the funds allocated to this project. Unfortunately, the technical challenges of the project were insurmountable. Optimizing the production of effector T cells would greatly benefit patients and we are hoping to revisit this in the near future.",True,,,,,,
93,126.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,"In the short term, the proposed research provides new prognostic markers to identify high-risk breast cancer patients for personalized treatment options. In the long term, the proposed research could lead to novel therapeutic regimens targeting cellular mechanotransduction for high-risk breast cancer patients with dense and stiff breast tumors.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,One,Submitted,NIH NCI,3000000.0,,,,,,,,,,,,,No,,No,,virtual rider,,,,,True,Published,10.1016/j.devcel.2020.05.031,,,,
94,127.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,True,False,False,False,Improved understanding of colorectal cancer.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,R01 GM138385 - Annotation of cell types in human colon tissue using Boolean analysis,1420781.0,Awarded,R01AI155696 Macrophage Polarization in Response to Infections and Inflammation,1906469.0,,,,,,,,,,Yes,Can help identify prognostic biomarkers of colon cancer.,Yes,Can move clinical diagnostic markers forward.,Rider,No,No,,,True,Published,10.1038/s41467-021-24470-5,Published,10.1053/j.gastro.2021.10.006,,
95,128.0,Progress Report #1,,,,,,,,,,,,,,,None,"The granted project helped to increase the quality of our research activities in the IMPPC at Barcelona. Specifically contributed to the securing a 10 million euros grant by the Spanish Ministry of Health to create a DNA bank (Genomes of Catalonia, GCAT) of some 50,000 individuals and its development during all these yeas up to the present. Colon cancer was and is one of the aspects of the GCAT endeavours and the Padres/Pedal grant was significantly related.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Two,Awarded,"Spanish Ministry of Health grant FIS, Alteraciones epigenéticas en cáncer colorrectal (CCR): papel de metaloproteinasas de matriz extracelular, remodeladores de cromatina, y asociación con el microbioma intestinal. ",200000.0,Awarded,"Spanish Ministry of Health, FIS Epigenetics in colorectal cancer phenotype: epigenetic aging and risk for multiple cancers.",250000.0,,,,,,,,,,No,,No,,No,No,No,,"I am so sorry not being more helpful, but I explained before that I was involved in the initial writing of the grant application, the conceptual development of the research plan after several meetings with the UCSD collaborators, but during the granting period I moved to Barcelona coincident with my official retirement from the SBP and the consequent change of status from from Professor to Adjunct Professor first and Emeritus Professor more recently, and could not be directly involved in the performance of the experiments pertinent to the project. The project continued at SBP by the collaborator there, Prof. Alex Strongin and the other PIs at UCSD. ",True,,,,,,
96,129.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,True,False,False,False,False,False,False,understanding the origins of ATRT will lead to improved therapies for this devastating brain cancer.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,additional funding would allow us to identify drugs that could be introduced into clinical trials,Yes,additional funding could lead to clinical trials for this disease,virtual rider,No,No,,Dr Furnari was key to the success of this project and would reach out to him regarding the benefits of further funding.,True,Accepted,10.1101/gad.339978.120,,,,
97,131.0,Progress Report #1,,,,,,,,,,,,,,,Abstract submitted for the 4D nucleome meeting 2021.,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,Virtual Rider,No,No,,,True,In progress,,,,,
98,132.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,The knowledge gained from this project will enable a better understanding of the molecular basis for different subtypes of leukemia and could eventually lead to new therapies that are specific to certain subtypes.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Additional funding would enable the continued collection of patient samples from RCHSD and would allow expansion of our study to additional leukemia types beyond B-ALL (for which we currently have the most samples).,No,,"Yes, I have participated as a virtual rider every year since 2016.",No,No,,,True,Accepted,doi.org/10.1093/nar/gkab621,In progress,,,
99,133.0,Progress Report #1,,,,,,,,,,,,,,,,Not applicable,Yes,False,False,False,False,False,True,False,The study may identify genes that are associated with poor outcome in acute leukemia.,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,No,No,No,,No,True,In progress,,,,,
100,134.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,My project identified potential tumor markers that could be used to risk stratify patients. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,No,,No,,,,,,,True,Published,,,,,
101,136.0,Progress Report #1,,,,,,,,,,,,,,,,,Yes,False,False,False,False,False,True,False,Pancreatitis biology is poorly understood due to the lack of human models. Furthermore it is unclear how pancreatitis promotes pancreas cancer. ,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No additional funding sources,,,,,,,,,,,,,,,,Yes,Additional funds would enable our team to continue accruing patients for our study and grow our understanding of inflammation and cancer of the pancreas. ,No,,"Yes, in May 2021 I participated virtually.",No,No,,,True,In progress,,,,,
102,138.0,Progress Report #1,,,,,,,,,,,,,,,"     Adam K. Fuhs S, Meisenhelder J,  Lesperance J, Aslanian A, Diedrich J, Moresco J, La Clair J, Zage P, Yates JR III, Hunter T. A Novel Role for Histidine Kinase Activity in Neuroblastoma Pathogenesis. Presented at the 11th International Congress on NME/NDPK/NM23/AWD gene family; Annecy, France, October 2019         Adam K, Fuhs S, Meisenhelder J, Lesperance J, Aslanian A, Diedrich J, Moresco J,  La Clair J, Zage P, Yates JR III, Hunter T. Chasing  the not so Elusive Histidine Phosphorylation  and Their Signaling in Neuroblastoma.  Presented at the 12th Annual World Protein &  Peptide Conference, Beijing, China, June 2019         Adam K, Fuhs S, Meisenhelder J,  Lesperance J, Aslanian A, Diedrich J, Moresco J,  La Clair J, Zage P, Yates JR III, Hunter T. Chasing  the not so Elusive Histidine Phosphorylation  and Their Signaling in Neuroblastoma.  Presented at the Advances in Biomedical  Research III, Split, Croatia, June 2019         Adam K. et al. ""Histidine kinases and the  missing phosphoproteome from prokaryotes  to eukaryotes."" Presented at the American  Society for Biochemistry and Molecular  Biology annual meeting, San Diego, CA, 2018",,Yes,True,False,False,False,False,False,False,"We expect our results will confirm the critical role of NME1 in neuroblastoma tumor development, growth, and spread and will serve to identify candidate therapeutic targets for currently available drugs as well as for the development of novel histidine kinase inhibitors that are likely to be elective against a wide range of pediatric and adult tumors.  These novel therapies and treatment  approaches would serve to improve outcomes for children with neuroblastoma and other solid tumors worldwide.",No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,No,False,False,False,False,False,False,False,,Five,Awarded,the Hartwell Foundation,300000.0,Awarded,Padres Pedal the Cause,100000.0,Awarded,Padres Pedal the Cause,100000.0,Submitted,Pediatric Cancer Research Foundation,750000.0,NIH R03CA273629-01,Submitted,150000.0,Yes,"Additional funding support would allow us to pursue studies to further identify and validate NME1-mediated signaling pathways in neuroblastoma preclinical models, to further pursue the functional significance of NME1 and histidine kinase signaling in pediatric tumor development, growth, and spread, and to identify novel candidate targets for therapies directed against targets of NME1 histidine kinase activity.",Yes,"Additional funding support would allow us to pursue screening studies at the Sanford  Burnham Prebys Medical Discovery Institute to identify candidate histidine kinase inhibitors that could be evaluated and developed as candidate therapeutic agents, eventually leading to animal studies and early phase clinical trials to evaluate the safety and efficacy of histidine kinase inhibitors in children with cancer.",I have participated as both a virtual participant and as a participant in spin classes  at Petco Park,Yes,No,,Funding from Padres Pedal the Cause has  been instrumental in building and  maintaining my research laboratory and  scienti#c productivity in San Diego and has  been greatly appreciated!,True,Published,,In progress,,,
103,139.0,Progress Report #1,,,,,,,,,,,,,,,"Kalagiri, R., Adam, K., and Hunter, T. 2020. Empirical evidence of cellular histidine phosphorylation by immunoblotting using pHis mAbs. Meth. Mol. Biol. 2077:181-191.    Adam, K., and Hunter, T. 2020. Subcellular localization of histidine phosphorylated proteins through indirect immunofluorescence. Meth. Mol. Biol. 2077:209-224.    Luhtala, N., and Hunter, T. 2020. Immunohistochemistry (IHC): chromogenic detection of 3-phosphohistidine proteins in formaldehyde-fixed, frozen mouse liver tissue sections. Meth. Mol. Biol. 2077:193-208.",,,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,,False,False,False,False,False,False,False,,,,,,,,,,,,,,,,,,,,,,,,,,,False,Published,doi: 10.3390/ijms21093319,,,,
